

AMIDO COMPOUNDS AS ROR γ t MODULATORS AND USES THEREOF**FIELD OF THE INVENTION**

[0001] This invention relates to amido compounds capable of modulating ROR γ t activity and uses of such compounds to treat diseases or conditions related to ROR γ t activity. More particularly, the amido compounds may be used to diminish inflammation associated with an inflammatory disease or condition or to reduce symptoms associated with an autoimmune disorder. Also encompassed herein, are compositions of amido compounds, pharmaceutical compositions of amido compounds, assays and methods for using same to identify compounds capable of modulating ROR γ t activity.

BACKGROUND OF THE INVENTION

[0002] The retinoic acid receptor-related orphan nuclear receptor (ROR) ROR γ and its isoform ROR γ t (collectively "ROR γ / γ t") play a major role in regulation of a variety of biological systems. To illustrate, ROR γ t has a central role in immune system development, homeostasis, and responses to microbial pathogens. For example, ROR γ t is required for the differentiation of Th17 cells (Ivanov, II et al. *Cell*, **2006**, 126, 1121-33), a subset of T helper cells that protect the host from infection by secreting inflammatory cytokines such as IL-17, IL-17 (also called IL-17A), IL-17F, IL-22, and TNF α . These cytokines are signaling proteins that have been shown to be essential in regulating numerous immune responses, including inflammatory responses to antigens. Th17 cells have also recently been shown to have important roles in activating and directing immune responses in a variety of autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA), inflammatory bowel disease (IBD), cancer (Weaver, C. et al. *Ann. Rev. Immunol.*, **2007**, 25, 821-52; Kryczek, I. et al. *J. Immunol.*, **2007**, 178, 6730-3; Cua, D. J. et al. *Nature*, **2003**, 421, 744-8; Langrish, C. L. et al. *J. Exp. Med.*, **2005**, 201, 233-40; Yen, D. et al. *J. Clin. Invest.*, **2006**, 116, 1310-6), and graft-versus-host disease (Carlson, M.J. et al. *Blood*, 28 October 2008. [Epub ahead of print]; Kappel, L.W. et al. *Blood*, 17 October 2008. [Epub ahead of print]). Th17 cells have also been implicated in asthma, psoriasis, rheumatoid arthritis, multiple sclerosis (Tzartos, J.S., et al. *Am. J. Pathology*, **2008**, 172, 146-55; Yu, J.J., and Gaffen, S.L. *Front. Biosci.*, **2008**, 13, 170-77; and Zheng, Y. et al. *Nature*, **2007**, 445, 648-51), and Crohn's disease (Duerr, R.H., et al. *Science*, **2006**, 314, 1461-63). Additionally, it has been shown that mice defective for expression of ROR γ t lack Th17 cells and are resistant to a variety of autoimmune diseases and that the absence of Th17-producing microbiota in the small intestine of mice alters the Th17: regulatory T (Treg)

cell balance with implications for intestinal immunity, tolerance, and susceptibility to inflammatory bowel diseases (Ivanov, I.I. *Cell Host & Microbe*, **2008**, 4, 337-49).

[0003] The formation of immune cell aggregates, such as cryptopatches (CP) and isolated lymphoid follicles (ILF), which contain ROR γ t expressing cells, is known to be a vital step in many immune responses. For example, CPs and ILFs are required for mucosal immunity and for production of the intestinal antibody IgA. Such immune responses can result in inflammation in various diseases, such as Crohn's disease. The ability to inhibit such immune responses by inhibiting the formation of immune cell aggregates may offer another way to treat diseases associated with such responses.

[0004] T-cells have also been demonstrated to play a role in diseases characterized by bone loss and degradation, such as osteoarthritis. For example, in autoimmune arthritis, activation of T cells results in bone destruction mediated by osteoclasts. Th17, whose differentiation is regulated by ROR γ t, has been shown to be osteoclastogenic, thus linking T cell activation and bone resorption (Sato, K. et al. *J. Ex. Med.*, **2008**, 203, 2673-82). Thus, the ability to regulate Th17 cell differentiation via ROR γ t modulation may offer a way to treat bone loss and degradation, such as that associated with autoimmune disease. Furthermore, interferon gamma (IFN- γ) suppresses osteoclast formation by rapidly degrading the RANK adaptor protein TRAF6 in the RANK-RANKL signaling pathway, and ROR γ t has been shown to down-regulate the production of IFN- γ (Ivanov, I.I. et al. *Cell*, **2006**, 126, 1121-33). Thus, the ability to regulate osteoclast formation through modulation of ROR γ t-mediated IFN- γ osteoclast suppression may provide additional methods to treat bone loss and degradation, such as that associated with autoimmune disease (e.g., osteoarthritis).

[0005] Circadian rhythm relates to an approximately daily periodicity in the biochemical, physiological or behavioral processes of living beings, including plants, animals, fungi and some bacteria. Members of the ROR family of orphan nuclear receptors have been implicated in regulation of control of circadian clock function by regulation of clock genes (Ueda, H. R. et al. *Nature*, **2002**, 418, 534-39; Sato, T. K. et al. *Neuron*, **2004**, 43, 527-37), and ROR γ /t has been implicated in the regulation of genes that govern circadian metabolism (Kumaki, Y. et al. *PNAS*, **2008**, 105, 14946-51; Liu, C. et al. *Nature*, **2007**, 447, 477-81). Moreover, ROR γ gene expression is known to oscillate in a circadian manner in metabolically active tissues such as liver and brown adipose tissue (Yang, X. et al., *Cell*, **2006**, 126, 801-10), which further confirms that a role exists for ROR γ in regulating circadian function. Hence, the ability to modulate ROR γ /t expression may also result in circadian rhythm regulation and treatment of disorders associated with disruption of circadian rhythm. Since circadian rhythm is integral in maintaining


metabolic levels, whose imbalance is linked to obesity and diabetes, modulators of ROR γ / γ t may also be useful in treating obesity and diabetes through regulation of circadian rhythm.

[0006] WO2011/112263 discloses diphenylsubstituted amido compounds as ROR γ / γ t modulators. WO2011/112264 discloses a series of compounds as ROR γ / γ t modulators.

[0007] In view of the above, a need exists for therapeutic agents, and corresponding pharmaceutical compositions and related methods of treatment that address conditions causally related to ROR γ t activity, and it is toward the fulfillment and satisfaction of that need, that the present invention is directed.

SUMMARY OF THE INVENTION

[0008] The present invention provides a method for preventing, treating or ameliorating in a mammal a disease or condition that is causally related to ROR γ or ROR γ t activity in vivo, which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to formula I:



wherein

each Cy¹ and Cy² is independently selected from substituted or unsubstituted aryl and heteroaryl;

each n₁ and n₂ is independently 1, 2, 3, 4 or 5;

each R^{1a} and R^{1b} is independently H, substituted or unsubstituted C₁-C₆ alkyl, or CN; or R^{1a} and R^{1b} joined together to form cycloalkyl ring;

R² is H, substituted or unsubstituted C₁-C₆ alkyl, or aryl;

or one of R^{1a} and R^{1b} is joined to the C of CR² to form a cyclopropyl ring; or R² is joined to the C of CR^{1a}R^{1b} to form a cyclopropyl ring;

each R³ and R⁴ is independently selected from H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylaryl amino, substituted or unsubstituted amino, substituted or

unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thiol; or any two adjacent R³ groups, or any two adjacent R⁴ groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring; each R⁵ and R⁶ is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroarylalkyl; or

R⁵ and R⁶, together with the N they are attached to, form a 4-12 membered substituted or unsubstituted heterocycloalkyl;

provided that

i) at least one of Cy¹ and Cy² is heteroaryl; or


ii) when each of Cy¹ and Cy² is phenyl; then at least one R³ is selected from CO₂H, CH₂CO₂H, COR^{3a}, CONR^{3a}R^{3b}, SO₃H, SOR^{3a}, SO₂R^{3a}, and heteroaryl; and wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;


or stereoisomers, isotopic variants and tautomers thereof.

[0009] In one embodiment, with respect to the compounds of formula I, R⁵ and R⁶ are joined together to form substituted or unsubstituted azetidiny, pyrrolidinyl, piperidinyl, piperiziny, morpholinyl, tetrahydroquinolinyl, indolinyl, or azepinyl. In another embodiment, R⁵ and R⁶ are joined together to form unsubstituted pyrrolidinyl, piperidinyl, piperiziny, morpholinyl, or azepinyl. In a particular embodiment, R⁵ and R⁶ are joined together to form piperidinyl or piperiziny.

[0010] In a further aspect, the present invention provides a compound according to formula IIIa-IIIc:




IIIa



IIIb

or



IIIc

and wherein n_1 , R^{1a} , R^{1b} , R^2 , R^3 , and R^4 , are as described for formula I; n_2 is 1, 2, or 3; each HET^1 and HET^2 is independently selected from heteroaryl;

$R^{3'}$ is R^3 ; $R^{4'}$ is R^4 ; n_1 is n_1 ; n_2 is n_2 ;

A is $CR^{8a}R^{8b}$, NR^{8a} , O, or S; m is 0 or 1;


each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; and t is 0, 1, 2, or 3;

R^{7a} is OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thio;

R^{7b} is R^4 ; or any two adjacent R^4 and R^{7b} groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring; and

each R^{8a} and R^{8b} is independently H, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
 or a pharmaceutically acceptable salt, solvate or prodrug thereof;
 or stereoisomers, isotopic variants and tautomers thereof;
 provided that

- i) when the compound is according to formula IIIa, then at least one R^3 is selected from CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; and wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring;
- ii) when the compound is according to formula IIIa, R^3 is $CONR^{3a}R^{3b}$, R^{3a} and R^{3b} are joined together to form a morpholino ring, m is 1, and A is O; then R^{7a} is other than H;
- iii) when the compound is



then the compound is in the form of a sodium, potassium, calcium, or ammonium salt;

- iv) the compound is other than the compounds listed in Table 1, wherein compound ID is 83, 84, 95, 100, 111, and 139;
- v) when the compound is according to formula IIIb; then R^{7a} is other than H;
- vi) when the compound is according to formula IIIb, HET^1 is furanyl or quinolin-3-yl, and each of $R^{3'}$ and R^4 is H; then R^{7a} is other than H or methoxy;
- vii) when the compound is according to formula IIIb, and HET^1 is pyrrolyl; then R^{7a} is other than H or methyl; and
- viii) when the compound is according to formula IIIb; then HET^1 is other than benzopyranyl.

[0011] In one particular embodiment, with respect to the compound of formula IIIa-IIIb, R^{7a} is other than H. In one particular embodiment, with respect to the compound of formula IIIa-IIIb, R^{7b} is other than H.

[0012] In one particular embodiment, with respect to the compound of formula IIIa-IIIc, when m is 1, A is N; then the N can be substituted or unsubstituted. In one embodiment A is NH. In another embodiment, A is N-R^{5a} and R^{5a} is as described herein.

[0013] In a further aspect, the present invention provides pharmaceutical compositions comprising a heterocyclic compound of the invention, and a pharmaceutical carrier, excipient or diluent. In this aspect of the invention, the pharmaceutical composition can comprise one or more of the compounds described herein. Moreover, the compounds of the present invention useful in the pharmaceutical compositions and treatment methods disclosed herein, are all pharmaceutically acceptable as prepared and used.

[0014] In a further aspect, this invention provides a method of treating a mammal susceptible to or afflicted with a condition from among those listed herein, and particularly, such condition as may be associated with ROR γ t. Such conditions include, without limitation, multiple sclerosis (and the animal model thereof, EAE), rheumatoid arthritis (and the animal model thereof, CIA), inflammatory bowel disease (IBD), cancer, graft-versus-host disease, asthma, psoriasis, diabetes, uveitis, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, arteriosclerosis, and *H. pylori* infections and ulcers resulting from such infection.

[0015] In a further aspect, an assay for screening to identify modulators of ROR γ /t transcriptional activity is envisioned, the assay comprising a first insect cell line that expresses a fusion protein (SEQ ID NO: 2; encoded by SEQ ID NO: 1) comprising a ROR γ /t sequence, wherein the ROR γ /t sequence does not comprise the DNA binding domain (DBD) of full length ROR γ /t and a yeast GAL4 DBD, wherein expression of the fusion protein is transcriptionally regulated by an inducible promoter, and wherein the first insect cell line further comprises a reporter, whose expression is upregulated in the presence of the fusion protein. Accordingly, the component of the fusion protein representative of ROR γ /t sequences is a DBD-deleted ROR γ /t sequence. The fusion protein is essentially a chimeric protein wherein the ROR γ /t DBD is deleted from the ROR γ /t sequences and replaced with the yeast GAL4 DNA binding domain DBD. In a particular embodiment, the Gal4 DNA binding domain (G4DBD) corresponds to amino acids 1 through 147 of Gal4 protein and the DBD-deleted ROR γ /t sequence is amino acids 79 to the carboxyl terminal end. Accordingly, the G4DBD corresponds to amino acids 1-147 of SEQ ID NO: 2 and the DBD-deleted ROR γ /t sequence corresponds to amino acids 148-564 of SEQ ID NO: 2. In a particular embodiment, the inducible promoter is a copper inducible promoter.

[0016] In an embodiment of the assay, the reporter is transcriptionally regulated by a plurality of copies of the GAL4 binding site enhancer (UAS) operatively linked to nucleic acid sequences encoding the reporter. In a particular embodiment of the assay, the plurality of copies of the GAL4 binding site enhancer (UAS) is between 1 and 5 copies. In a more particular embodiment, the reporter is the firefly luciferase reporter.

[0017] In an aspect of the assay, the first insect cell line is the S2 cell line. In another aspect of the assay, the fusion protein is encoded by nucleic acids that are integrated into the genome of the first insect cell line or encoded by extrachromosomal nucleic acids incorporated into the first insect cell line. Accordingly, the assay may relate to stably transfected cell line or a transiently transfected cell line. The choice of stably or transiently transfected cell line depends, in part, on the number of compounds to be tested and availability and cost of assay reagents required.

[0018] As described herein, the assay may further comprise a second insect cell line that expresses a second fusion protein (SEQ ID NO: 4; encoded by SEQ ID NO: 3) comprising a ROR α sequence, wherein the ROR α sequence does not comprise the DBD of full length ROR α sequence and a yeast GAL4 DBD; a third insect cell line that expresses a third fusion protein (SEQ ID NO: 6; encoded by SEQ ID NO: 5) comprising a DHR3 sequence, wherein the DHR3 sequence does not comprise the DNA binding domain (DBD) of full length DHR3 sequence and a yeast GAL4 DBD, and a fourth insect cell line that expresses a fourth fusion protein (SEQ ID NO: 8; encoded by SEQ ID NO: 7) comprising a transcriptionally active domain of general transcriptional activator VP16 and a yeast GAL4 DBD, wherein expression of the second, third and fourth fusion proteins is transcriptionally regulated by inducible promoters. In a particular embodiment, the DBD-deleted mouse ROR α sequence is amino acids 142 to the carboxyl terminal end of mouse ROR α and the DBD-deleted *Drosophila* DHR3 is amino acids 120 to the carboxyl terminal end of *Drosophila* DHR3. Accordingly, the G4DBD corresponds to amino acids 1-147 of SEQ ID NOs: 4, 6, and 8 and the DBD-deleted ROR α sequence corresponds to amino acids 148-529 of SEQ ID NO: 4, the DBD-deleted DHR3 sequence corresponds to amino acids 148-513 of SEQ ID NO: 6, and the VP16 sequence corresponds to amino acids 148-231 of SEQ ID NO: 8. In an embodiment, inducible promoters regulating expression of the first, second, third, and fourth fusion proteins are identical promoters. In yet another embodiment, the inducible promoters regulating expression of the first, second, third, and fourth fusion proteins are copper inducible promoters.

[0019] Methods for using the assay of the invention are also encompassed herein. Such methods include those involving use of the cell-based assay systems described herein to screen diverse compound libraries, such as those available from research institutions, federal agencies,

and/or commercial vendors, to identify modulators of ROR γ / γ t transcriptional activity.

Modulators of ROR γ / γ t transcriptional activity may be identified based on results determined using the first insect cell-based assay system described herein alone or in combination with at least one of the second, third, and fourth insect cell-based assay systems described herein to identify compounds that are specific modulators of ROR γ / γ t transcriptional activity.

Modulators identified using assays described herein may be identified as inhibitors or agonists of ROR γ / γ t transcriptional activity. Compounds identified using the cell based systems described herein may be assessed in secondary screens, also described herein and understood in the art, to validate their identity as *bona fide* modulators of ROR γ / γ t transcriptional activity.

[0020] Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 shows fluorescence activated cell sorter (FACS) plot analyses revealing the effects of NCGC00242624 and NCGC00238427 on mouse Th17 differentiation.

NCGC00242624, a more stable compound, suppresses mouse Th17 cell differentiation with similar activity to NCGC00238427.

[0022] Figure 2 shows FACS plot analyses revealing that NCGC00242624 and NCGC00238427 selectively suppress human Th17, but not human Th1, cell differentiation. Compound NCGC00242626 serves as a negative control along with the carrier control DMSO, neither of which exhibits the ability to suppress human Th17 or Th1 cell differentiation.

[0023] Figure 3 shows FACS plot analyses revealing that NCGC00242624 and NCGC00238427 selectively inhibit ROR γ t dependent, but not ROR α dependent, human Th17 cell differentiation. Compound NCGC00242626 serves as a negative control along with the carrier control DMSO, neither of which exhibits the ability to inhibit ROR γ t dependent human Th17 cell differentiation.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0024] When describing the compounds, pharmaceutical compositions containing such compounds and methods of using such compounds and compositions, the following terms have the following meanings unless otherwise indicated. It should also be understood that any of the moieties defined forth below may be substituted with a variety of substituents, and that the respective definitions are intended to include such substituted moieties within their scope. It

should be further understood that the terms “groups” and “radicals” can be considered interchangeable when used herein.

[0025] “Acyl” refers to a radical $-C(O)R^{20}$, where R^{20} is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl as defined herein. Representative examples include, but are not limited to, formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl and the like.

[0026] “Acylamino” refers to a radical $-NR^{21}C(O)R^{22}$, where R^{21} is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl and R^{22} is hydrogen, alkyl, alkoxy, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl or heteroarylalkyl, as defined herein. Representative examples include, but are not limited to, formylamino, acetylamino, cyclohexylcarbonylamino, cyclohexylmethyl-carbonylamino, benzoylamino, benzylcarbonylamino and the like.

[0027] “Acyloxy” refers to the group $-OC(O)R^{23}$ where R^{23} is hydrogen, alkyl, aryl or cycloalkyl.

[0028] “Substituted alkenyl” includes those groups recited in the definition of “substituted” herein, and particularly refers to an alkenyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂- and aryl-S(O)₂-.

[0029] “Alkoxy” refers to the group $-OR^{24}$ where R^{24} is alkyl. Particular alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.

[0030] “Substituted alkoxy” includes those groups recited in the definition of “substituted” herein, and particularly refers to an alkoxy group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂- and aryl-S(O)₂-.

[0031] “Alkoxycarbonylamino” refers to the group $-NR^{25}C(O)OR^{26}$, where R^{25} is hydrogen, alkyl, aryl or cycloalkyl, and R^{26} is alkyl or cycloalkyl.

[0032] “Alkyl” refers to monovalent saturated alkane radical groups particularly having up to about 11 carbon atoms, more particularly as a lower alkyl, from 1 to 8 carbon atoms and still more particularly, from 1 to 6 carbon atoms. The hydrocarbon chain may be either straight-chained or branched. This term is exemplified by groups such as methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *iso*-butyl, *tert*-butyl, *n*-hexyl, *n*-octyl, *tert*-octyl and the like. The term “lower alkyl” refers to alkyl groups having 1 to 6 carbon atoms. The term “alkyl” also includes “cycloalkyls” as defined below.

[0033] “Substituted alkyl” includes those groups recited in the definition of “substituted” herein, and particularly refers to an alkyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, heteroaryl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂-, and aryl-S(O)₂-.

[0034] “Alkylene” refers to divalent saturated alkene radical groups having 1 to 11 carbon atoms and more particularly 1 to 6 carbon atoms which can be straight-chained or branched. This term is exemplified by groups such as methylene (-CH₂-), ethylene (-CH₂CH₂-), the propylene isomers (*e.g.*, -CH₂CH₂CH₂- and -CH(CH₃)CH₂-) and the like.

[0035] “Substituted alkylene” includes those groups recited in the definition of “substituted” herein, and particularly refers to an alkylene group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, amino-carbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂- and aryl-S(O)₂-.

[0036] “Alkenyl” refers to monovalent olefinically unsaturated hydrocarbyl groups preferably having 2 to 11 carbon atoms, particularly, from 2 to 8 carbon atoms, and more particularly, from 2 to 6 carbon atoms, which can be straight-chained or branched and having at least 1 and particularly from 1 to 2 sites of olefinic unsaturation. Particular alkenyl groups include ethenyl (-CH=CH₂), *n*-propenyl (-CH₂CH=CH₂), isopropenyl (-C(CH₃)=CH₂), vinyl and substituted vinyl, and the like.

[0037] “Alkenylene” refers to divalent olefinically unsaturated hydrocarbyl groups particularly having up to about 11 carbon atoms and more particularly 2 to 6 carbon atoms which

can be straight-chained or branched and having at least 1 and particularly from 1 to 2 sites of olefinic unsaturation. This term is exemplified by groups such as ethenylene ($-\text{CH}=\text{CH}-$), the propenylene isomers (*e.g.*, $-\text{CH}=\text{CHCH}_2-$ and $-\text{C}(\text{CH}_3)=\text{CH}-$ and $-\text{CH}=\text{C}(\text{CH}_3)-$) and the like.

[0038] “Alkynyl” refers to acetylenically or alkynically unsaturated hydrocarbyl groups particularly having 2 to 11 carbon atoms, and more particularly 2 to 6 carbon atoms which can be straight-chained or branched and having at least 1 and particularly from 1 to 2 sites of alkynyl unsaturation. Particular non-limiting examples of alkynyl groups include acetylenic, ethynyl ($-\text{C}\equiv\text{CH}$), propargyl ($-\text{CH}_2\text{C}\equiv\text{CH}$), and the like.

[0039] “Substituted alkynyl” includes those groups recited in the definition of “substituted” herein, and particularly refers to an alkynyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂- and aryl-S(O)₂-.

[0040] “Alkanoyl” or “acyl” as used herein refers to the group $\text{R}^{27}-\text{C}(\text{O})-$, where R^{27} is hydrogen or alkyl as defined above.

[0041] “Aryl” refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, *αs*-indacene, *s*-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like. Particularly, an aryl group comprises from 6 to 14 carbon atoms.

[0042] “Substituted Aryl” includes those groups recited in the definition of “substituted” herein, and particularly refers to an aryl group that may optionally be substituted with 1 or more substituents, for instance from 1 to 5 substituents, particularly 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, alkoxycarbonyl, alkyl, substituted alkyl, alkynyl, substituted alkynyl, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂- and aryl-S(O)₂-.

[0043] "Fused Aryl" refers to an aryl having two of its ring carbon in common with a second aryl ring or with an aliphatic ring.

[0044] "Alkaryl" refers to an aryl group, as defined above, substituted with one or more alkyl groups, as defined above.

[0045] "Aralkyl" or "arylalkyl" refers to an alkyl group, as defined above, substituted with one or more aryl groups, as defined above.

[0046] "Aryloxy" refers to -O-aryl groups wherein "aryl" is as defined above.

[0047] "Alkylamino" refers to the group alkyl-NR²⁸R²⁹, wherein each of R²⁸ and R²⁹ are independently selected from hydrogen and alkyl.

[0048] "Arylamino" refers to the group aryl-NR³⁰R³¹, wherein each of R³⁰ and R³¹ are independently selected from hydrogen, aryl and heteroaryl.

[0049] "Alkoxyamino" refers to a radical -N(H)OR³² where R³² represents an alkyl or cycloalkyl group as defined herein.

[0050] "Alkoxy carbonyl" refers to a radical -C(O)-alkoxy where alkoxy is as defined herein.

[0051] "Alkylarylamino" refers to a radical -NR³³R³⁴ where R³³ represents an alkyl or cycloalkyl group and R³⁴ is an aryl as defined herein.

[0052] "Alkylsulfonyl" refers to a radical -S(O)₂R³⁵ where R³⁵ is an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl and the like.

[0053] "Alkylsulfinyl" refers to a radical -S(O)R³⁵ where R³⁵ is an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl and the like.

[0054] "Alkylthio" refers to a radical -SR³⁵ where R³⁵ is an alkyl or cycloalkyl group as defined herein that may be optionally substituted as defined herein. Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, and the like.

[0055] "Amino" refers to the radical -NH₂.

[0056] "Substituted amino" includes those groups recited in the definition of "substituted" herein, and particularly refers to the group -N(R³⁶)₂ where each R³⁶ is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, cycloalkyl, substituted cycloalkyl, and where both R groups are joined to form an alkylene group. When both R groups are hydrogen, -N(R³⁶)₂ is an amino group.

[0057] “Aminocarbonyl” refers to the group $-C(O)NR^{37}R^{37}$ where each R^{37} is independently hydrogen, alkyl, aryl and cycloalkyl, or where the R^{37} groups are joined to form an alkylene group.

[0058] “Aminocarbonylamino” refers to the group $-NR^{38}C(O)NR^{38}R^{38}$ where each R^{38} is independently hydrogen, alkyl, aryl or cycloalkyl, or where two R groups are joined to form an alkylene group.

[0059] “Aminocarbonyloxy” refers to the group $-OC(O)NR^{39}R^{39}$ where each R^{39} is independently hydrogen, alkyl, aryl or cycloalkyl, or where the R groups are joined to form an alkylene group.

[0060] “Arylalkyloxy” refers to an $-O$ -arylalkyl radical where arylalkyl is as defined herein.

[0061] “Arylamino” means a radical $-NHR^{40}$ where R^{40} represents an aryl group as defined herein.

[0062] “Aryloxycarbonyl” refers to a radical $-C(O)-O$ -aryl where aryl is as defined herein.

[0063] “Arylsulfonyl” refers to a radical $-S(O)_2R^{41}$ where R^{41} is an aryl or heteroaryl group as defined herein.

[0064] “Azido” refers to the radical $-N_3$.

“Bicycloaryl” refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent bicycloaromatic ring system. Typical bicycloaryl groups include, but are not limited to, groups derived from indane, indene, naphthalene, tetrahydronaphthalene, and the like. Particularly, an aryl group comprises from 8 to 11 carbon atoms.

[0065] “Bicycloheteroaryl” refers to a monovalent bicycloheteroaromatic group derived by the removal of one hydrogen atom from a single atom of a parent bicycloheteroaromatic ring system. Typical bicycloheteroaryl groups include, but are not limited to, groups derived from benzofuran, benzimidazole, benzindazole, benzdioxane, chromene, chromane, cinnoline, phthalazine, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, benzothiazole, benzoxazole, naphthyridine, benzoxadiazole, pteridine, purine, benzopyran, benzpyrazine, pyridopyrimidine, quinazoline, quinoline, quinolizine, quinoxaline, benzomorphan, tetrahydroisoquinoline, tetrahydroquinoline, and the like. Preferably, the bicycloheteroaryl group is between 9-11 membered bicycloheteroaryl, with 5-10 membered heteroaryl being particularly preferred. Particular bicycloheteroaryl groups are those derived from benzothiophene, benzofuran, benzothiazole, indole, quinoline, isoquinoline, benzimidazole, benzoxazole and benzdioxane.

[0066] "Carbamoyl" refers to the radical $-C(O)N(R^{42})_2$ where each R^{42} group is independently hydrogen, alkyl, cycloalkyl or aryl, as defined herein, which may be optionally substituted as defined herein.

[0067] "Carboxy" refers to the radical $-C(O)OH$.

[0068] "Carboxyamino" refers to the radical $-N(H)C(O)OH$.

[0069] "Cycloalkyl" refers to cyclic hydrocarbyl groups having from 3 to about 10 carbon atoms and having a single cyclic ring or multiple condensed rings, including fused and bridged ring systems, which optionally can be substituted with from 1 to 3 alkyl groups. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like, and multiple ring structures such as adamantanyl, and the like.

[0070] "Substituted cycloalkyl" includes those groups recited in the definition of "substituted" herein, and particularly refers to a cycloalkyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂- and aryl-S(O)₂-.

[0071] "Cycloalkoxy" refers to the group $-OR^{43}$ where R^{43} is cycloalkyl. Such cycloalkoxy groups include, by way of example, cyclopentoxy, cyclohexoxy and the like.

[0072] "Cycloalkenyl" refers to cyclic hydrocarbyl groups having from 3 to 10 carbon atoms and having a single cyclic ring or multiple condensed rings, including fused and bridged ring systems and having at least one and particularly from 1 to 2 sites of olefinic unsaturation. Such cycloalkenyl groups include, by way of example, single ring structures such as cyclohexenyl, cyclopentenyl, cyclopropenyl, and the like.

[0073] "Substituted cycloalkenyl" includes those groups recited in the definition of "substituted" herein, and particularly refers to a cycloalkenyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂- and aryl-S(O)₂-.

[0074] “Fused Cycloalkenyl” refers to a cycloalkenyl having two of its ring carbon atoms in common with a second aliphatic or aromatic ring and having its olefinic unsaturation located to impart aromaticity to the cycloalkenyl ring.

[0075] “Cyanato” refers to the radical -OCN.

[0076] “Cyano” refers to the radical -CN.

[0077] “Dialkylamino” means a radical $-NR^{44}R^{45}$ where R^{44} and R^{45} independently represent an alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, or substituted heteroaryl group as defined herein.

[0078] “Ethenyl” refers to substituted or unsubstituted $-(C=C)-$.

[0079] “Ethylene” refers to substituted or unsubstituted $-(C-C)-$.

[0080] “Ethynyl” refers to $-(C\equiv C)-$.


[0081] “Halo” or “halogen” refers to fluoro, chloro, bromo and iodo. Preferred halo groups are either fluoro or chloro.

[0082] “Hydroxy” refers to the radical -OH.

[0083] “Nitro” refers to the radical $-NO_2$.

[0084] “Substituted” refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s). Typical substituents include, but are not limited to, $-X$, $-R^{46}$, $-O^-$, $=O$, $-OR^{46}$, $-SR^{46}$, $-S^-$, $=S$, $-NR^{46}R^{47}$, $=NR^{46}$, $-CX_3$, $-CF_3$, $-CN$, $-OCN$, $-SCN$, $-NO$, $-NO_2$, $=N_2$, $-N_3$, $-S(O)_2O^-$, $-S(O)_2OH$, $-S(O)_2R^{46}$, $-OS(O)_2O^-$, $-OS(O)_2R^{46}$, $-P(O)(O^-)_2$, $-P(O)(OR^{46})(O^-)$, $-OP(O)(OR^{46})(OR^{47})$, $-C(O)R^{46}$, $-C(S)R^{46}$, $-C(O)OR^{46}$, $-C(O)NR^{46}R^{47}$, $-C(O)O^-$, $-C(S)OR^{46}$, $-NR^{48}C(O)NR^{46}R^{47}$, $-NR^{48}C(S)NR^{46}R^{47}$, $-NR^{49}C(NR^{48})NR^{46}R^{47}$ and $-C(NR^{48})NR^{46}R^{47}$, where each X is independently a halogen; each R^{46} , R^{47} , R^{48} and R^{49} are independently hydrogen, alkyl, substituted alkyl, aryl, substituted alkyl, arylalkyl, substituted alkyl, cycloalkyl, substituted alkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, $-NR^{50}R^{51}$, $-C(O)R^{50}$ or $-S(O)_2R^{50}$ or optionally R^{50} and R^{51} together with the atom to which they are both attached form a cycloheteroalkyl or substituted cycloheteroalkyl ring; and R^{50} and R^{51} are independently hydrogen, alkyl, substituted alkyl, aryl, substituted alkyl, arylalkyl, substituted alkyl, cycloalkyl, substituted alkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl.

[0085] Examples of representative substituted aryls include the following




[0086] In these formulae one of R⁵² and R⁵³ may be hydrogen and at least one of R⁵² and R⁵³ is each independently selected from alkyl, alkenyl, alkynyl, cycloheteroalkyl, alkanoyl, alkoxy, aryloxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR⁵⁴COR⁵⁵, NR⁵⁴SOR⁵⁵, NR⁵⁴SO₂R⁵⁷, COOalkyl, COOaryl, CONR⁵⁴R⁵⁵, CONR⁵⁴OR⁵⁵, NR⁵⁴R⁵⁵, SO₂NR⁵⁴R⁵⁵, S-alkyl, S-alkyl, SOalkyl, SO₂alkyl, Saryl, SOaryl, SO₂aryl; or R⁵² and R⁵³ may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or more heteroatoms selected from the group N, O or S. R⁵⁴, R⁵⁵, and R⁵⁶ are independently hydrogen, alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, cycloheteroalkyl, aryl, substituted aryl, heteroaryl, substituted or hetero alkyl or the like.

[0087] “Hetero” when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, *e.g.* heteroalkyl, cycloalkyl, *e.g.* cycloheteroalkyl, aryl, *e.g.* heteroaryl, cycloalkenyl, cycloheteroalkenyl, and the like having from 1 to 5, and especially from 1 to 3 heteroatoms.


[0088] “Heteroaryl” refers to a monovalent heteroaromatic group derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system. Typical heteroaryl groups include, but are not limited to, groups derived from acridine, arsinole, carbazole, β -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. Preferably, the heteroaryl group is between 5-15 membered heteroaryl, with 5-10 membered heteroaryl being particularly preferred. Particular heteroaryl groups are those derived from thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.

[0089] Examples of representative heteroaryls include the following:




wherein each Y is selected from carbonyl, N, NR⁵⁸, O, and S; and R⁵⁸ is independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, heteroalkyl or the like.

[0090] As used herein, the term “cycloheteroalkyl” refers to a stable heterocyclic non-aromatic ring and fused rings containing one or more heteroatoms independently selected from N, O and S. A fused heterocyclic ring system may include carbocyclic rings and need only include one heterocyclic ring. Examples of heterocyclic rings include, but are not limited to, piperazinyl, homopiperazinyl, piperidinyl and morpholinyl, and are shown in the following illustrative examples:




wherein each X is selected from CR⁵⁸₂, NR⁵⁸, O and S; and each Y is selected from NR⁵⁸, O and S; and R⁵⁸ is independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, heteroalkyl or the like. These cycloheteroalkyl rings may be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂- and aryl-S(O)₂-. Substituting groups include carbonyl or thiocarbonyl which provide, for example, lactam and urea derivatives.

[0091] Examples of representative cycloheteroalkenyls include the following:



wherein each X is selected from CR^{58}_2 , NR^{58} , O and S; and each Y is selected from carbonyl, N, NR^{58} , O and S; and R^{58} is independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, heteroalkyl or the like.

[0092] Examples of representative aryl having hetero atoms containing substitution include the following:



wherein each X is selected from C-R^{58}_2 , NR^{58} , O and S; and each Y is selected from carbonyl, NR^{58} , O and S; and R^{58} is independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, heteroalkyl or the like.

[0093] “Hetero substituent” refers to a halo, O, S or N atom-containing functionality that may be present as an R^4 in a R^4C group present as substituents directly on A, B, W, Y or Z of the compounds of this invention or may be present as a substituent in the “substituted” aryl and aliphatic groups present in the compounds.

Examples of hetero substituents include:

- halo,
- $-\text{NO}_2$, $-\text{NH}_2$, $-\text{NHR}^{59}$, $-\text{N}(\text{R}^{59})_2$,
- $-\text{NRCOR}$, $-\text{NR}^{59}\text{SOR}^{59}$, $-\text{NR}^{59}\text{SO}_2\text{R}^{59}$, OH, CN,
- $-\text{CO}_2\text{H}$,
- $-\text{R}^{59}-\text{OH}$, $-\text{O-R}^{59}$, $-\text{COOR}^{59}$,
- $-\text{CON}(\text{R}^{59})_2$, $-\text{CONROR}^{59}$,
- $-\text{SO}_3\text{H}$, $-\text{R}^{59}-\text{S}$, $-\text{SO}_2\text{N}(\text{R}^{59})_2$,
- $-\text{S}(\text{O})\text{R}^{59}$, $-\text{S}(\text{O})_2\text{R}^{59}$

wherein each R^{59} is independently an aryl or aliphatic, optionally with substitution. Among hetero substituents containing R^{59} groups, preference is given to those materials having aryl and alkyl R^{59} groups as defined herein. Preferred hetero substituents are those listed above.

[0094] “Hydrogen bond donor” group refers to a group containing O-H, or N-H functionality. Examples of “hydrogen bond donor” groups include -OH, -NH₂, and -NH-R^{59a} and wherein R^{59a} is alkyl, cycloalkyl, aryl, or heteroaryl.

[0095] “Dihydroxyphosphoryl” refers to the radical -PO(OH)₂.

[0096] “Substituted dihydroxyphosphoryl” includes those groups recited in the definition of “substituted” herein, and particularly refers to a dihydroxyphosphoryl radical wherein one or both of the hydroxyl groups are substituted. Suitable substituents are described in detail below.

[0097] “Aminohydroxyphosphoryl” refers to the radical -PO(OH)NH₂.

[0098] “Substituted aminohydroxyphosphoryl” includes those groups recited in the definition of “substituted” herein, and particularly refers to an aminohydroxyphosphoryl wherein the amino group is substituted with one or two substituents. Suitable substituents are described in detail below. In certain embodiments, the hydroxyl group can also be substituted.

[0099] “Thioalkoxy” refers to the group -SR⁶⁰ where R⁶⁰ is alkyl.

[00100] “Substituted thioalkoxy” includes those groups recited in the definition of “substituted” herein, and particularly refers to a thioalkoxy group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)₂- and aryl-S(O)₂-.

[00101] “Sulfanyl” refers to the radical HS-. “Substituted sulfanyl” refers to a radical such as RS- wherein R is any substituent described herein.

[00102] “Sulfonyl” refers to the divalent radical -S(O)₂-. “Substituted sulfonyl” refers to a radical such as R⁶¹-(O₂)S- wherein R⁶¹ is any substituent described herein. “Aminosulfonyl” or “Sulfonamide” refers to the radical H₂N(O₂)S-, and “substituted aminosulfonyl” “substituted sulfonamide” refers to a radical such as R⁶²₂N(O₂)S- wherein each R⁶² is independently any substituent described herein.

[00103] “Sulfone” refers to the group -SO₂R⁶³. In particular embodiments, R⁶³ is selected from H, lower alkyl, alkyl, aryl and heteroaryl.

[00104] “Thioaryloxy” refers to the group -SR⁶⁴ where R⁶⁴ is aryl.

[00105] “Thioketo” refers to the group =S.

[00106] “Thiol” refers to the group -SH.

[00107] One having ordinary skill in the art of organic synthesis will recognize that the maximum number of heteroatoms in a stable, chemically feasible heterocyclic ring, whether it is

aromatic or non aromatic, is determined by the size of the ring, the degree of unsaturation and the valence of the heteroatoms. In general, a heterocyclic ring may have one to four heteroatoms so long as the heteroaromatic ring is chemically feasible and stable.

[00108] “Pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.

[00109] “Pharmaceutically acceptable salt” refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, *e.g.*, an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like. The term “pharmaceutically acceptable cation” refers to a non toxic, acceptable cationic counter-ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like.

[00110] “Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.

[00111] “Preventing” or “prevention” refers to a reduction in risk of acquiring a disease or disorder (*i.e.*, causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).

[00112] “Prodrugs” refers to compounds, including derivatives of the compounds of the invention, which have cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active *in vivo*. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.

[00113] “Solvate” refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. Conventional solvents include water, ethanol, acetic acid and the like. The compounds of the invention may be prepared *e.g.* in crystalline form and may be solvated or hydrated. Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non-stoichiometric solvates.

[00114] “Subject” includes humans. The terms “human,” “patient” and “subject” are used interchangeably herein.

[00115] “Therapeutically effective amount” means the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The “therapeutically effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.

[00116] “Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (*i.e.*, arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (*e.g.*, stabilization of a discernible symptom), physiologically, (*e.g.*, stabilization of a physical parameter), or both.

[00117] As used herein, the term “operably linked” refers to a regulatory sequence capable of mediating the expression of a coding sequence and which is placed in a DNA molecule (*e.g.*, an expression vector) in an appropriate position relative to the coding sequence so as to effect expression of the coding sequence. This same definition is sometimes applied to the arrangement of coding sequences and transcription control elements (*e.g.* promoters, enhancers, and termination elements) in an expression vector. This definition is also sometimes applied to the arrangement of nucleic acid sequences of a first and a second nucleic acid molecule wherein a hybrid nucleic acid molecule is generated.

[00118] A “vector” is a replicon, such as a plasmid, cosmid, bacmid, phage or virus, to which another genetic sequence or element (either DNA or RNA) may be attached so as to bring about the replication of the attached sequence or element.

[00119] An "expression vector" or "expression operon" refers to a nucleic acid segment that may possess transcriptional and translational control sequences, such as promoters, enhancers, translational start signals (e.g., ATG or AUG codons), polyadenylation signals, terminators, and the like, and which facilitate the expression of a polypeptide coding sequence in a host cell or organism.

[00120] The terms "transform", "transfect", or "transduce", shall refer to any method or means by which a nucleic acid is introduced into a cell or host organism and may be used interchangeably to convey the same meaning. Such methods include, but are not limited to, transfection, electroporation, microinjection, PEG-fusion and the like.

[00121] The introduced nucleic acid may or may not be integrated (covalently linked) into nucleic acid of the recipient cell or organism. In bacterial, yeast, plant and mammalian cells, for example, the introduced nucleic acid may be maintained as an episomal element or independent replicon such as a plasmid. Alternatively, the introduced nucleic acid may become integrated into the nucleic acid of the recipient cell or organism and be stably maintained in that cell or organism and further passed on or inherited to progeny cells or organisms of the recipient cell or organism. In other applications, the introduced nucleic acid may exist in the recipient cell or host organism only transiently.

[00122] The phrase "consisting essentially of" when referring to a particular nucleotide or amino acid means a sequence having the properties of a given SEQ ID NO:. For example, when used in reference to an amino acid sequence, the phrase includes the sequence per se and molecular modifications that would not affect the basic and novel characteristics of the sequence.

[00123] Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but in the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. Preferred are the C₁ to C₈ alkyl, C₂-C₈ alkenyl, aryl, C₇-C₁₂ substituted aryl, and C₇-C₁₂ arylalkyl esters of the compounds of the invention.

[00124] As used herein, the term "isotopic variant" refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such

compound. For example, an “isotopic variant” of a compound can contain one or more non-radioactive isotopes, such as for example, deuterium (^2H or D), carbon-13 (^{13}C), nitrogen-15 (^{15}N), or the like. It will be understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be $^2\text{H}/\text{D}$, any carbon may be ^{13}C , or any nitrogen may be ^{15}N , and that the presence and placement of such atoms may be determined within the skill of the art. Likewise, the invention may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, *i.e.* ^3H , and carbon-14, *i.e.* ^{14}C , are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Further, compounds may be prepared that are substituted with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

[00125] All isotopic variants of the compounds provided herein, radioactive or not, are intended to be encompassed within the scope of the invention.

[00126] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”.

[00127] Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (*i.e.*, as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.


[00128] “Tautomers” refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of π electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base.

[00129] Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.

[00130] The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.

THE COMPOUNDS

[00131] The present invention provides a method for preventing, treating or ameliorating in a mammal a disease or condition that is causally related to the activity of the ROR γ or ROR γ t in vivo, which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to formula I:



or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;

wherein

each Cy¹ and Cy² is independently selected from substituted or unsubstituted aryl and heteroaryl;

each n₁ and n₂ is independently 1, 2, 3, 4 or 5;

each R^{1a} and R^{1b} is independently H, substituted or unsubstituted C₁-C₆ alkyl, or CN; or

R^{1a} and R^{1b} joined together to form cycloalkyl ring;

R² is H, substituted or unsubstituted C₁-C₆ alkyl, or aryl;

or one of R^{1a} and R^{1b} is joined to the C of CR² to form a cyclopropyl ring; or R² is joined to the C of CR^{1a}R^{1b} to form a cyclopropyl ring;


each R³ and R⁴ is independently selected from H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or

unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thiol; or any two adjacent R³ groups, or any two adjacent R⁴ groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring; each R⁵ and R⁶ is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroarylalkyl; or

R⁵ and R⁶, together with the N they are attached to, form a 4-12 membered substituted or unsubstituted heterocycloalkyl;

provided that

- i) at least one of Cy¹ and Cy² is heteroaryl; and
- ii) when the compound is




then the compound is in the form of an acid addition salt;

or

provided that

i) when each of Cy¹ and Cy² is phenyl; then at least one R³ is selected from CO₂H, CH₂CO₂H, COR^{3a}, CONR^{3a}R^{3b}, SO₃H, SOR^{3a}, SO₂R^{3a}, and heteroaryl; and wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring;

- ii) when the compound is



then the compound is in the form of a sodium, potassium, calcium, or ammonium salt; and

iii) the compound is other than the compounds listed in Table 1, wherein compound ID is 83, 84, 95, 100, 111, and 139.

[00132] In certain aspects, the present invention provides a method for preventing, treating or ameliorating in a mammal a disease or condition that is causally related to the activity of the ROR γ or ROR γ t in vivo, which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to formula I; or a pharmaceutically acceptable salt, solvate or prodrug thereof; or stereoisomers, isotopic variants and tautomers thereof; wherein

one of Cy¹ and Cy² is substituted or unsubstituted heteroaryl; and the other is selected from substituted or unsubstituted aryl and heteroaryl;

each n₁ and n₂ is independently 1, 2, 3, 4 or 5;

each R^{1a} and R^{1b} is independently H, substituted or unsubstituted C₁-C₆ alkyl, or CN; or R^{1a} and R^{1b} joined together to form cycloalkyl ring;

R² is H, substituted or unsubstituted C₁-C₆ alkyl, or aryl;

or one of R^{1a} and R^{1b} is joined to the C of CR² to form a cyclopropyl ring; or R² is joined to the C of CR^{1a}R^{1b} to form a cyclopropyl ring;

each R³ and R⁴ is independently selected from H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and

thiol; or any two adjacent R³ groups, or any two adjacent R⁴ groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring;

each R⁵ and R⁶ is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroarylalkyl; or

R⁵ and R⁶, together with the N they are attached to, form a 4-12 membered substituted or unsubstituted heterocycloalkyl;

provided that

i) when the compound is Compound 146; then the compound is in the form of an acid addition salt.

[00133] In certain aspects, the present invention provides a method for preventing, treating or ameliorating in a mammal a disease or condition that is causally related to the activity of the ROR γ or ROR γ t in vivo, which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to formula I; or a pharmaceutically acceptable salt, solvate or prodrug thereof; or stereoisomers, isotopic variants and tautomers thereof; wherein

each Cy1 and Cy2 is independently selected from substituted or unsubstituted phenyl;

each n1 and n2 is independently 1, 2, 3, 4 or 5;

each R^{1a} and R^{1b} is independently H, substituted or unsubstituted C₁-C₆ alkyl, or CN; or

R^{1a} and R^{1b} joined together to form cycloalkyl ring;

R² is H, substituted or unsubstituted C₁-C₆ alkyl, or aryl;

or one of R^{1a} and R^{1b} is joined to the C of CR² to form a cyclopropyl ring; or R² is joined to the C of CR^{1a}R^{1b} to form a cyclopropyl ring;

each R³ and R⁴ is independently selected from H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and

thiol; or any two adjacent R^3 groups, or any two adjacent R^4 groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring; each R^5 and R^6 is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroarylalkyl; or

R^5 and R^6 , together with the N they are attached to, form a 4-12 membered substituted or unsubstituted heterocycloalkyl;

provided that at least one R^3 is selected from CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; and wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring; provided that

- i) when the compound is Compound 99 or Compound 101; then the compound is in the form of a sodium, potassium, calcium, or ammonium salt; and
- ii) the compound is other than the compounds listed in Table 1, wherein compound ID is 83, 84, 95, 100, 111, and 139.

[00134] In certain aspects, the invention provides composition of matter and pharmaceutical composition for Compound 99 or Compound 101.

[00135] In one particular embodiment, with respect to the compounds of formula I, the compound is Compound 99 or Compound 101 and the compound is in the form of a sodium, potassium, calcium, or ammonium salt.

[00136] In another embodiment, with respect to the compounds of formula I, the compound is a sodium, potassium, calcium, or ammonium salt of any one of compounds of formula I, wherein R^3 is CO_2H , CH_2CO_2H . In one particular embodiment, the compound is Compound 99. In another particular embodiment, the compound is Compound 101. In another particular embodiment, the compound is Compound 201 (as depicted in Table 1). In another particular embodiment, the compound is Compound 202 (as depicted in Table 1A).

[00137] In certain aspects, the invention provides composition of matter and pharmaceutical composition for the compound is a sodium, potassium, calcium, or ammonium salt of any one of compounds of formula I, wherein R^3 is CO_2H , CH_2CO_2H . In one particular embodiment, the compound is Compound 99. In another particular embodiment, the compound is Compound 101. In another particular embodiment, the compound is Compound 201 (as depicted in Table 1). In another particular embodiment, the compound is Compound 202 (as depicted in Table 1A).

[00138] In one embodiment, with respect to the compounds of formula I, the compound is a compound listed in Table 1; and wherein the Compound ID is 83, 84, 95, 100, 111, or 139.

[00139] In one embodiment, the present invention does not include the compounds with Compound IDs 83, 84, 95, 100, 111, or 139.

[00140] In one embodiment, with respect to the compounds of formula I, each R⁵ and R⁶ is independently selected from H, substituted or unsubstituted alkyl, substituted and unsubstituted cycloalkyl, and substituted and unsubstituted phenyl.

[00141] In another embodiment, with respect to the compounds of formula I, one of R⁵ and R⁶ is H or Me; and the other is independently selected from H, substituted or unsubstituted alkyl, substituted and unsubstituted cycloalkyl, and substituted and unsubstituted phenyl.

[00142] In another embodiment, with respect to the compounds of formula I, each R⁵ and R⁶ is independently selected from substituted or unsubstituted alkyl.

[00143] In another embodiment, with respect to the compounds of formula I, each R⁵ and R⁶ is independently selected from unsubstituted alkyl.

[00144] In one particular embodiment, with respect to the compounds of formula I, each R⁵ and R⁶ is independently selected from H, Me, Et, n-Pr, i-Pr, n-Bu, and t-Bu.

[00145] In another embodiment, with respect to the compounds of formula I, each R⁵ and R⁶ is independently selected from H, and alkyl substituted with hydroxyl, amino, alkylamino, dialkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

[00146] In another particular embodiment, with respect to the compounds of formula I, each R⁵ and R⁶ is independently selected from H, Me, Et, hydroxyethyl, hydroxypropyl, aminoethyl, aminopropyl, dimethylaminoethyl, dimethylaminopropyl, piperidinoethyl, morpholinoethyl, cyclopropylmethyl, benzyl, phenethyl, and furanylmethyl.

[00147] In one embodiment, with respect to the compounds of formula I, each R⁵ and R⁶ is independently selected from H, and cycloalkyl.

[00148] In another embodiment, with respect to the compounds of formula I, each R⁵ and R⁶ is independently selected from H, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.


[00149] In another particular embodiment, with respect to the compounds of formula I, R⁵ is H; and R⁶ is selected from hydroxyethyl, hydroxypropyl, aminoethyl, aminopropyl, dimethylaminoethyl, dimethylaminopropyl, piperidinoethyl, morpholinoethyl, cyclopropylmethyl, cyclohexyl, benzyl, phenethyl, and furanylmethyl.

[00150] In yet another particular embodiment, with respect to the compounds of formula I, R⁵ and R⁶ are joined together to form a 4-12 membered substituted or unsubstituted heterocycloalkyl.

[00151] In yet another particular embodiment, with respect to the compounds of formula I, R^5 and R^6 are joined together to form azetidiny, pyrrolidinyl, piperidinyl, piperiziny, morpholinyl, tetrahydroquinolinyl, indolinyl, or azepiny, unsubstituted or substituted with one or more alkyl, substituted alkyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, alkoxy, hydroxyl, CN, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, amido, acyl, aroyl, or –CO-alkoxy.

[00152] In yet another particular embodiment, with respect to the compounds of formula I, R^5 and R^6 are joined together to form substituted or unsubstituted azetidiny, substituted or unsubstituted pyrrolidinyl, piperidinyl, piperiziny, morpholinyl, or azepiny. In another embodiment, R^5 and R^6 are joined together to form unsubstituted pyrrolidinyl, piperidinyl, piperiziny, morpholinyl, or azepiny. In a particular embodiment, R^5 and R^6 are joined together to form piperidinyl or piperiziny.

[00153] In one embodiment, with respect to the compounds of formula I, the compound is according to formula IIa, IIb, IIc, IId, IIe, or IIf:



and wherein Cy^1 , Cy^2 , n_1 , n_2 , R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are as described for formula I; and each R^{5a} and R^{5b} is independently H, alkyl, substituted alkyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, alkoxy, hydroxyl, CN, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, amido, acyl, aroyl, or –CO-alkoxy.

[00154] In one embodiment, with respect to the compounds of formula I-IIIf, each of Cy^1 and Cy^2 is phenyl.

[00155] In one embodiment, with respect to the compounds of formula I-IIId, each of pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl can be substituted with more than one R^{5a}

group. In one embodiment, with respect to the compounds of formula I-IIId, each of pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl is substituted with one R^{5a} group. In another embodiment, each of pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl is substituted with two, three or four R^{5a} groups. In a particular embodiment, each of pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl is substituted with two R^{5a} groups. In one embodiment, each R^{5a} is unsubstituted alkyl. In another embodiment, each R^{5a} is independently Me, Et, i-Pr, n-Pr, i-Bu, n-Bu, or t-Bu.

[00156] In one embodiment, with respect to the compounds of formula I-IIIf, one of Cy¹ and Cy² is heteroaryl; and the other is phenyl.

[00157] In one embodiment, with respect to the compounds of formula I-IIIf, each of Cy¹ and Cy² is heteroaryl.

[00158] In one embodiment, with respect to the compounds of formula I-IIIf, n₂ is 1, 2, or 3.

[00159] In one embodiment, with respect to the compounds of formula I-IIIf, n₂ is 1, 2, or 3; and each R⁴ is independently selected from halo, C₁-C₆ alkyl, CN, OH, and C₁-C₆ alkoxy.

[00160] In one embodiment, with respect to the compounds of formulae I-IIIf, n₂ is 1, 2, or 3; and each R⁴ is independently selected from Cl, Me, OH, and C₁-C₆ alkoxy. In a particular embodiment, n₂ is 3.

[00161] In one embodiment, with respect to the compounds of formula I-IIIf, R⁴ is H, alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, alkoxyalkyl, amido, hydroxyl, cyano, or alkoxy.

[00162] In one embodiment, with respect to the compounds of formula I-IIIf, R⁴ is H, halo, C₁-C₆ alkyl, CN, OH, or C₁-C₆ alkoxy.


[00163] In one embodiment, with respect to the compounds of formula I-IIIf, R⁴ is H, Cl, F, Me, CF₃, CN, OH, or OMe.

[00164] In another particular embodiment, with respect to the compounds of formulae I-IIIf, n₂ is 1; and R⁴ is Cl, F, Me, Et, i-Pr, OMe, CF₃, CN or OH. In one embodiment R⁴ is at 4- or para- position of the phenyl ring. In another embodiment, R⁴ is 4-Cl, 4-F, 4-Me, 4-Et, 4-i-Pr, 4-OMe, 4-CF₃, 4-CN or 4-OH. In yet another embodiment, R⁴ is 3-Cl, 3-F, 3-Me, 3-Et, 3-i-Pr, 3-OMe, 3-CF₃, 3-CN or 3-OH.


[00165] In one particular embodiment, with respect to the compounds of formulae I-IIIf, n₁ is 1; R⁴ is 4-NMe₂. In another particular embodiment, R⁴ is 4-Me. In another particular embodiment, R⁴ is 2-Me. In another particular embodiment, R⁴ is 4-OMe. In another particular embodiment, R⁴ is 4-OEt.

[00166] In one particular embodiment, with respect to the compounds of formulae I-IIf, two adjacent R^4 groups joined together to form $-O-CH_2-O-$, $-O-CF_2-O-$, $-O-CH_2-CH_2-O-$, $-O-CH_2-CH_2-CH_2-O-$, or $-CH=CH-CH=CH-$.


[00167] In one particular embodiment, with respect to the compounds of formulae I-IIf, the group




[00168] In another particular embodiment, with respect to the compounds of formulae I-IIf, the group



[00169] In another particular embodiment, with respect to the compounds of formulae I-IIf, the group





[00170] In another particular embodiment, with respect to the compounds of formulae I-IIf, the group




wherein the naphthyl is unsubstituted or substituted with one or more R^4 groups.

[00171] In one embodiment, with respect to the compounds of formula I, the compound is according to formula IIIa, IIIb, or IIIc:



or



or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;

and wherein n_1 , R^{1a} , R^{1b} , R^2 , R^3 , and R^4 are as described for formula I; n_2 is 1, 2, or 3;

each HET^1 and HET^2 is independently selected from heteroaryl;

$R^{3'}$ is R^3 ; $R^{4'}$ is R^4 ; $n'1$ is n_1 ; $n'2$ is n_2 ;

A is $CR^{8a}R^{8b}$, NR^{8a} , O, or S; m is 0 or 1;

each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; and t is 0, 1, 2, or 3;

R^{7a} is H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thio;

R^{7b} is R^4 ; or any two adjacent R^4 and R^{7b} groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring; and

each R^{8a} and R^{8b} is independently H, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

provided that

i) when the compound is according to formula IIIa, then at least one R^3 is selected from CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; and wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring;

ii) when the compound is Compound 99 or Compound 101, then the compound is in the form of a sodium, potassium, calcium, or ammonium salt; and

iii) the compound is other than the compounds listed in Table 1, wherein compound ID is 83, 84, 95, 100, 111, and 139.

[00172] In a further aspect, the present invention provides composition of a compound according to formula IIIa, IIIb, or IIIc; or a pharmaceutically acceptable salt, solvate or prodrug thereof; or stereoisomers, isotopic variants and tautomers thereof; and wherein

$n1$, R^{1a} , R^{1b} , R^2 , R^3 , and R^4 , are as described for formula I; $n2$ is 1, 2, or 3;

each HET^1 and HET^2 is independently selected from heteroaryl;

$R^{3'}$ is R^3 ; $R^{4'}$ is R^4 ; $n'1$ is $n1$; $n'2$ is $n2$;

A is $CR^{8a}R^{8b}$, NR^{8a} , O, or S; m is 0 or 1;

each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; and t is 0, 1, 2, or 3;

R^{7a} is OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkythio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thio;

R^{7b} is R^4 ; or any two adjacent R^4 and R^{7b} groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring; and

each R^{8a} and R^{8b} is independently H, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

provided that

- i) when the compound is according to formula IIIa, at least one R^3 is selected from CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; and wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring;
- ii) when the compound is according to formula IIIa, R^3 is $CONR^{3a}R^{3b}$, R^{3a} and R^{3b} are joined together to form a morpholino ring, m is 1, and A is O; then R^{7a} is other than H;
- iii) when the compound is Compound 99 or Compound 101, then the compound is in the form of a sodium, potassium, calcium, or ammonium salt;
- iv) the compound is other than the compounds listed in Table 1, wherein compound ID is 83, 84, 95, 100, 111, and 139;
- v) when the compound is according to formula IIIb; then R^{7a} is other than H;
- vi) when the compound is according to formula IIIb, HET^1 is furanyl or quinolin-3-yl, and each of $R^{3'}$ and R^4 is H; then R^{7a} is other than H or methoxy;
- vii) when the compound is according to formula IIIb, and HET^1 is pyrrolyl; then R^{7a} is other than H or methyl; and
- viii) when the compound is according to formula IIIb; then HET^1 is other than benzopyranyl.

[00173] For the sake of clarity, the present invention does not include composition of matter for the compounds according to formulae IIIa; wherein one of R^3 's is not CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; and wherein R^{3a} and R^{3b} are as described herein.

[00174] For the sake of clarity, the present invention includes composition of matter for the compounds according to formula IIIa; wherein one of R^3 's is CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; and wherein R^{3a} and R^{3b} are as described herein.

[00175] For the sake of clarity, the present invention does not include composition of matter for the compounds according to formula IIIa; wherein one of R^3 's is $CONR^{3a}R^{3b}$, R^{3a} and R^{3b} are joined together to form a morpholino ring, m is 1, A is O and R^{7a} is H.

[00176] For the sake of clarity, the present invention does not include composition of matter for the compounds according to formula IIIb; wherein R^{7a} is H.

[00177] For the sake of clarity, the present invention does not include composition of matter for the compounds according to formula IIIb; wherein HET¹ is furanyl or quinolin-3-yl, and each of R^{3'} and R⁴ is H; and R^{7a} is H or methoxy.

[00178] For the sake of clarity, the present invention does not include composition of matter for the compounds according to formulae IIIb; HET¹ is pyrrolyl and R^{7a} is H or methyl.

[00179] For the sake of clarity, the present invention does not include composition of matter for the compounds according to formula IIIb; HET¹ is benzopyranyl.

[00180] In one embodiment, with respect to the compounds of formula IIIa-IIIc, t is 0. In another embodiment, t is 1 or 2.

[00181] In one embodiment, with respect to the compounds of formula IIIa-IIIb, R^{7a} is other than H. In another embodiment, with respect to the compounds of formula IIIa-IIIb, R^{7b} is other than H.

[00182] In one embodiment, with respect to the compounds of formula IIIa-IIIb, each of R^{7a} and R^{7b} is independently OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thio.

[00183] In one embodiment, with respect to the compounds of formula IIIa-IIIb, each of R^{7a} and R^{7b} is independently OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, CN, halo, amido, or haloalkyl.

[00184] In one embodiment, with respect to the compounds of formula IIIa-IIIb, each of R^{7a} and R^{7b} is independently halo, C₁-C₆ alkyl, CN, OH, or C₁-C₆ alkoxy.

[00185] In one embodiment, with respect to the compounds of formula IIIa-IIIb, each of R^{7a} and R^{7b} is independently Cl, F, Me, CF₃, CN, OH, or OMe.

[00186] In one embodiment, with respect to the compounds of formula IIIa-IIIb, one of R^{7a} and R^{7b} is OH; and the other is alkoxy.

[00187] In one embodiment, with respect to the compounds of formula IIIa-IIIb, each of R^{7a} and R^{7b} is OH or alkoxy.

[00188] In one embodiment, with respect to the compounds of formula IIIa-IIIb, one of R^{7a} and R^{7b} is OH; and the other is OMe.

[00189] In one embodiment, with respect to the compounds of formula I-IIIb, R^{1a} and R^{1b} is independently H, CN, or Me.

[00190] In one embodiment, with respect to the compounds of formula I-IIIb, each of R^{1a} and R^{1b} is H. In another embodiment each of R^{1a} and R^{1b} is Me.

[00191] In one embodiment, with respect to the compounds of formula I-IIIb, one of R^{1a} and R^{1b} is H; and the other is CN.

[00192] In one embodiment, with respect to the compounds of formula IIIa-IIIc, m is 0.


[00193] In one embodiment, with respect to the compounds of formula IIIa-IIIc, m is 1; and A is C or N. In one embodiment, A is CH_2 , CHR^{5a} , or $CR^{5a}R^{5a}$. In another embodiment A is NH or NR^{5a} . In a yet another embodiment, A is O. In a further embodiment, A is S.

[00194] In one embodiment, with respect to the compounds of formula IIIb-IIIc, HET^1 is selected from pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, triazolyl, oxadiazolyl, and thiadiazolyl.

[00195] In one embodiment, with respect to the compounds of formula IIIb-IIIc, HET^1 is selected from pyridyl, pyrimidyl, and pyrazinyl. In one particular embodiment, HET^1 is pyridyl.

[00196] In one embodiment, with respect to the compounds of formula IIIb-IIIc, HET^1 is selected from indolyl, benzimidazolyl, 2-oxobenzimidazolyl, benzofuranyl, benzothiazolyl, and benzthiophenyl. In another embodiment, HET^1 is benzothiazol-1-yl.

[00197] In one embodiment, with respect to the compounds of formula IIIb-IIIc, the group




[00198] In one embodiment, with respect to the compounds of formula IIIb-IIIc, HET^2 is selected from pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, triazolyl, oxadiazolyl, and thiadiazolyl.


[00199] In one embodiment, with respect to the compounds of formula IIIb-IIIc, HET^2 is selected from pyridyl, pyrimidyl, and pyrazinyl.

[00200] In one embodiment, with respect to the compounds of formula IIIb-IIIc, HET^2 is selected from indolyl, benzimidazolyl, 2-oxobenzimidazolyl, benzofuranyl, benzothiazolyl, and benzthiophenyl.


[00201] In one embodiment, with respect to the compounds of formula IIIb-IIIc, the group



[00202] In one embodiment, with respect to the compounds of formula IIIa-IIIc, the group




is substituted or unsubstituted




[00203] In one embodiment, with respect to the compounds of formula IIIa-IIIc, when m is 1 and A is N, the N is substituted with H or R^{5a} and the R^{5a} is as described herein. In one particular embodiment, A is N- R^{5a} , and R^{5a} is alkyl, substituted alkyl, acyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl. In one embodiment, R^{5a} is methoxyalkyl.


[00204] In one embodiment, with respect to the compounds of formula IIIa-IIIc, the group



is substituted or unsubstituted




[00205] In one particular embodiment, with respect to the compounds of formulae IIIa-IIIb, the group




and wherein each R^{4a} is independently selected from alkoxy.

[00206] In another particular embodiment, with respect to the compounds of formulae IIIa-IIIb, the group



[00207] In one embodiment, with respect to the compounds of formula I, the compound is according to formula IVa, IVb, IVc, IVd, IVe, or IVf:



or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;

and wherein $n1$, R^2 , R^4 , R^5 , and R^6 are as described for formula I;

R^3 is selected from CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring; each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; t is 0, 1, 2, or 3; provided that

- i) when the compound is Compound 99 or Compound 101, then the compound is in the form of a sodium, potassium, calcium, or ammonium salt; and
- ii) the compound is other than Compound 95, 100, 111, or 139 (as depicted in

Table 1).

- [00208] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^3 is CO_2H .
- [00209] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^3 is SO_3H .
- [00210] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^3 is CH_2CO_2H .
- [00211] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^3 is heteroaryl.
- [00212] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^3 is pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, triazolyl, oxadiazolyl, thiadiazolyl, and tetrazolyl.
- [00213] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^3 is 1,3,4-triazolyl or tetrazol-5-yl.
- [00214] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^3 is $CONR^{3a}R^{3b}$; wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In another embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^3 is $CONR^{3a}R^{3b}$; and R^{3a} and R^{3b} joined together to form a substituted or unsubstituted heterocyclic ring.
- [00215] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^{3b} is H.
- [00216] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^{3b} is alkyl.
- [00217] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^{3b} is Me, Et, or i-Pr.


[00218] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, R^3 is selected from COR^{3a} , SOR^{3a} , and SO_2R^{3a} ; wherein R^{3a} is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[00219] In one embodiment, R^{3a} is alkyl.


[00220] In one embodiment, R^{3a} is Me, Et, or i-Pr.

[00221] In one embodiment, with respect to the formula I-IIIa, and IVa-IVf, NH is $N-R^{5a}$, and R^{5a} is alkyl, substituted alkyl, acyl, haloalkyl, hydroxyalkyl, or alkoxyalkyl. In one embodiment, R^{5a} is methoxyalkyl.


[00222] In one particular embodiment, with respect to the compounds of formulae I-IIIa, and IVa-IVf, the group




[00223] In another particular embodiment, with respect to the compounds of formulae I-IIIa, and IVa-IVf, the group



[00224] In another particular embodiment, with respect to the compounds of formulae I-IIIa, and IVa-IVf, the group




[00225] In another particular embodiment, with respect to the compounds of formulae I-IIIa, and IVa-IVf, the group




wherein the R^{3a} and R^{3b} are as described herein.

[00226] In one particular embodiment, with respect to the compounds of formulae IIIb-IIIc, the group



and wherein $R^{3'}$ and n' are as described herein.

[00227] In one particular embodiment, with respect to the compounds of formulae IIIb-IIIc, the group




and wherein $R^{3'}$ and n' are as described herein.

[00228] In one embodiment, each $R^{3'}$ is H.

[00229] In one embodiment, each $R^{3'}$ is independently selected from halo, alkyl, amino, dialkylamino, carboxy, trifluoromethyl, and alkoxy. In another embodiment, each $R^{3'}$ is independently selected from Cl, Me, CF_3 , OMe, CO_2H , NH_2 , and NMe_2 .

[00230] In one embodiment, with respect to the compounds of formula I, the compound is according to formula Va, Vb, Vc, Vd, Ve, or Vf:





or a pharmaceutically acceptable salt, solvate or prodrug thereof;




or stereoisomers, isotopic variants and tautomers thereof;

and wherein R^2 , R^5 , and R^6 are as described for formula I; each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; t is 0, 1, 2, or 3.


[00231] In one embodiment, with respect to the compounds of formula Va, Vb, Vc, Vd,

Ve, or Vf, the 2-thienyl group, , is replaced with 2-benzothiazolyl .

[00232] In another embodiment, with respect to the compounds of formula Va, Vb, Vc,

Vd, Ve, or Vf, the 2-thienyl group, , is replaced with ; or .

[00233] In one embodiment, with respect to the compounds of formula I-III, the compound is according to formula VIa, VIb, VIc, VId, VIe, or VIIf.



or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;

and wherein R^2 , R^5 , and R^6 are as described for formula I; each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; and t is 0, 1, 2, or 3.

[00234] In one embodiment, with respect to the formula Va-VI, NH is $N-R^{5a}$, and R^{5a} is alkyl, substituted alkyl, haloalkyl, hydroxyalkyl, or methoxyalkyl.

[00235] In one embodiment, with respect to the compounds of formulae I-VI, R^2 is OH.

[00236] In one embodiment, with respect to the compounds of formulae I-VI, R^2 is H, substituted or unsubstituted C_1 - C_6 alkyl, or substituted or unsubstituted phenyl.

[00237] In another embodiment, with respect to the compounds of formulae I-VI, R^2 is H, Me, OH, or Ph.

[00238] In one particular embodiment, with respect to the compounds of formulae I-VI, R^2 is H.

[00239] In another particular embodiment, with respect to the compounds of formulae IIIa-VI, t is 0. In another embodiment t is 1 or 2.

[00240] In one embodiment, with respect to the compounds of formulae IIIa-VI, t is 1; and R^{5a} is OH, Ph, benzyl, or Me. In another embodiment, t is 1; and R^{5a} is Me, Et, n-Pr, or n-Bu. In one particular embodiment, t is 1; and R^{5a} is 3-Me, 3-Et, 3-n-Pr, or 3-n-Bu.

[00241] In one embodiment, with respect to the compounds of formulae IIIa-VI, t is 2; and each R^{5a} is independently OH, Ph, benzyl, or Me. In another embodiment, t is 2; and one R^{5a}

is 3-Me and the other is 5-Me. In another embodiment, t is 2; and one R^{5a} is 3-Me and the other is 5-Me.

[00242] In one embodiment, with respect to the compounds of formulae IIa-IIId, IIIa-VIf, R^{5a} is OH, or Me.

[00243] In one particular embodiment, with respect to the compounds of formulae IIa-IIId, IIIa-VIf, R^{5a} is Me.

[00244] In one particular embodiment, with respect to the compounds of formulae IIa-IIId, IIIa-VIf, R^{5a} is Ph.


[00245] In one particular embodiment, with respect to the compounds of formulae IIa-IIId, IIIa-VIf, R^{5a} is benzyl.

[00246] In another particular embodiment, with respect to the compounds of formulae IIa-IIId, IIIa-VIf, R^{5a} is 3-Me.

[00247] In one particular embodiment, with respect to the compounds of formulae I-VIf, R⁵, when present, is H. In another embodiment, R⁵, when present, is Me or Et.

[00248] In one particular embodiment, with respect to the compounds of formulae I-VIf, R⁵, when present, is H. In another embodiment, R⁵, when present, is Me, Et, n-Pr, or n-Bu. In yet another embodiment, R⁵, when present, is n-pentyl, n-hexyl, or n-heptyl.

[00249] In one particular embodiment, with respect to the compounds of formula I, the compound is according to formula VIIa, VIIb, VIIc, VIId, VIIf, or VIIf:




and wherein R^{5b} is H or Me;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.


[00250] In one particular embodiment, with respect to the compounds of formulae VIIa-VIIc, R^{5b} is H. In another embodiment, R^{5b} is Me.

[00251] In another particular embodiment, with respect to the compounds of formula I, the compound is according to formula VIIIa, VIIIb, or VIIIc:



or a pharmaceutically acceptable salt, solvate or prodrug thereof;
or stereoisomers, isotopic variants and tautomers thereof.


[00252] In one particular embodiment, with respect to the compounds of formula I, the compound is according to formula IXa IXb, or IXc:



or a pharmaceutically acceptable salt, solvate or prodrug thereof;
or stereoisomers, isotopic variants and tautomers thereof.

[00253] In one particular embodiment, with respect to the compounds of formula IXa, the compound is a sodium salt.

[00254] In one particular embodiment, with respect to the compounds of formula I-III, the compound is according to formula Xa, Xb, or Xc:




and wherein R^{5b} is H or Me;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.

[00255] In one particular embodiment, with respect to the compounds of formula I-III, the compound is according to formula XIa, XIb, or XIc:




and wherein R^{5b} is H or Me;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.

[00256] In one particular embodiment, with respect to the compounds of formula I-III, the compound is according to formula XIIa, XIIb, or XIIc:



and wherein R^{5b} is H or Me;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.

[00257] In certain embodiments, the invention provides compounds according to formula Xa, Xb, Xc, XIa, XIb, XIc, XIIa, XIIb, or XIIc.

[00258] In certain embodiments, with respect to the method of the invention, the compound is according to formula I; and the compound is Compound 99, or 101 (Table 1).

[00259] In certain embodiments, with respect to the method of the invention, the compound is according to formula I; and the compound is Compound 95, 100, 111, or 139 (Table 1).

[00260] In certain embodiments, the invention provides composition of matter for compounds Compound 95, 99, 100, 101, 111, or 139 (Table 1).

[00261] In one particular embodiment, with respect to the compounds of formula I, the compound is any one of the compounds listed in Table 1.

[00262] In one particular embodiment, with respect to the compounds of formula I, the compound is any one of the compounds listed in Table 1, Table 1A, and Table 1B; and wherein the Compound ID is 70, 79 106-108, 142, 202-206, 301-349 or 350.

[00263] In one particular embodiment, with respect to the compounds of formula I, the compound is any one of the compounds listed in Table 1A; and wherein the Compound ID is 202.

[00264] In one particular embodiment, with respect to the compounds of formula I, the compound is a sodium salt of Compound 201 or 202.

[00265] In one particular embodiment, with respect to the compounds of formula I, the compound is any one of the compounds listed in Table 1C.

[00266] In another aspect, the present invention provides pharmaceutical composition of a compound according to formulae I-XIc.

[00267] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula IIIa.

[00268] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula IIIb.

[00269] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula IIIc.

[00270] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula IVa-IVf.

[00271] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula Va-Vf.

[00272] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula VIa-VIf.

[00273] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula VIIa-VIIIf.

[00274] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula VIIIa-VIIIc.

[00275] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula IXa-IXc.

[00276] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula Xa-Xc.

[00277] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula XIa-XIc.

[00278] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds according to formula XIIa-XIIc.

[00279] In one particular aspect, the present invention provides composition of matter and pharmaceutical composition of the compounds listed in Table 1A, 1B, or 1C; or a pharmaceutically acceptable salt, solvate or prodrug thereof; or stereoisomers, isotopic variants and tautomers thereof.

[00280] In one embodiment, with respect to the method of treatment, the disease or condition is autoimmune disease.

[00281] In one embodiment, with respect to the method of treatment, the disease or condition is inflammatory disease.

[00282] In one embodiment, with respect to the method of treatment, the disease or condition is selected from arthritis, diabetes, multiple sclerosis (and the animal model thereof, EAE), uveitis, rheumatoid arthritis (and the animal model thereof, CIA), psoriasis, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, atherosclerosis, cancer, graft-versus-host disease, *H. pylori* infections and ulcers resulting from such infection, and inflammatory bowel diseases.

[00283] In one embodiment, with respect to the method of treatment, the disease or condition is selected from Crohn's disease, ulcerative colitis, sprue and food allergies.

[00284] In certain aspects, the present invention provides prodrugs and derivatives of the compounds according to the formulae above. Prodrugs are derivatives of the compounds of the invention, which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention, which are pharmaceutically active, *in vivo*. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.

[00285] Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type

prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. Preferred are the C₁ to C₈ alkyl, C₂-C₈ alkenyl, aryl, C₇-C₁₂ substituted aryl, and C₇-C₁₂ arylalkyl esters of the compounds of the invention.

PHARMACEUTICAL COMPOSITIONS

[00286] When employed as pharmaceuticals, the compounds of this invention are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

[00287] Generally, the compounds of this invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound -administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[00288] The pharmaceutical compositions of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. Depending on the intended route of delivery, the compounds of this invention are preferably formulated as either injectable or oral compositions or as salves, as lotions or as patches all for transdermal administration.

[00289] The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the furansulfonic acid compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

[00290] Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a

sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[00291] Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As before, the active compound in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.

[00292] Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight. When formulated as a ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example an oil-in-water cream base. Such transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration of stability of the active ingredients or the formulation. All such known transdermal formulations and ingredients are included within the scope of this invention.

[00293] The compounds of this invention can also be administered by a transdermal device. Accordingly, transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.

[00294] The above-described components for orally administrable, injectable or topically administrable compositions are merely representative. Other materials as well as processing techniques and the like are set forth in Part 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.

[00295] The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[00296] The following formulation examples illustrate representative pharmaceutical compositions of this invention. The present invention, however, is not limited to the following pharmaceutical compositions.

Formulation 1 - Tablets

[00297] A compound of the invention is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active amide compound per tablet) in a tablet press.

Formulation 2 - Capsules

[00298] A compound of the invention is admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active amide compound per capsule).

Formulation 3 - Liquid

[00299] A compound of the invention (125 mg), sucrose (1.75 g) and xanthan gum (4 mg) are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water. Sodium benzoate (10 mg), flavor, and color are diluted with water and added with stirring. Sufficient water is then added to produce a total volume of 5 mL.

Formulation 4 - Tablets

[00300] A compound of the invention is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active amide compound) in a tablet press.

Formulation 5 - Injection

[00301] A compound of the invention is dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/mL.

Formulation 6 - Topical

[00302] Stearyl alcohol (250 g) and a white petrolatum (250 g) are melted at about 75°C and then a mixture of a compound of the invention (50 g) methylparaben (0.25 g), propylparaben (0.15 g), sodium lauryl sulfate (10 g), and propylene glycol (120 g) dissolved in water (about 370 g) is added and the resulting mixture is stirred until it congeals.

METHODS OF TREATMENT

[00303] The present compounds are used as therapeutic agents for the treatment of conditions in mammals that are causally related or attributable to ROR γ t activity. Accordingly, the compounds and pharmaceutical compositions of this invention find use as therapeutics for preventing and/or treating a variety of inflammatory conditions and autoimmune disorders in mammals, including humans.

[00304] In a method of treatment aspect, this invention provides a method of treating a mammal susceptible to or afflicted with a condition associated with an inflammatory condition and/or an autoimmune disorder, which method comprises administering an effective amount of one or more of the pharmaceutical compositions just described.

[00305] In additional method of treatment aspects, this invention provides methods of treating a mammal susceptible to or afflicted with an inflammatory condition or autoimmune

disorder causally related or attributable to ROR γ t activity. Such condition and disorders include, without limitation, arthritis, diabetes, multiple sclerosis (and the animal model thereof, EAE), uveitis, rheumatoid arthritis (and the animal model thereof, CIA), psoriasis, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, atherosclerosis, cancer, graft-versus-host disease, *H. pylori* infections and ulcers resulting from such infection, and inflammatory bowel diseases. Such methods comprise administering an effective condition-treating or condition-preventing amount of one or more of the pharmaceutical compositions just described.

[00306] The present inventors have shown that treatment of wildtype cells with ROR γ t inhibitor digoxin resulted in changes in gene expression that were very similar to those observed in ROR γ t-deficient cells. See Huh et al. (2011) Digoxin and its derivatives suppress Th17 cell differentiation by antagonizing ROR γ t activity; *Nature* **472**, 486–490 (28 April 2011), the entire contents of which is incorporated herein by reference. That being the case, ROR γ t inhibitors can be used to treat any diseases caused by ROR γ or ROR γ t expressing cells, including Th17, NK22, and other innate lymphoid cells. The pro-atherogenic contribution of IL-17 to atherosclerotic lesions, for example, suggests that atherosclerosis can be treated efficaciously with the compounds and compositions described herein. See Chen et al. J Innate Immun. 2010;2(4):325-33. Epub 2010 May 7, the entire contents of which is incorporated herein by reference.

[00307] As a further aspect of the invention there is provided the present compounds for use as a pharmaceutical especially in the treatment or prevention of the aforementioned conditions and diseases. Also provided herein is the use of the present compounds in the manufacture of a medicament for the treatment or prevention of one of the aforementioned conditions and diseases.

[00308] Injection dose levels range from about 0.1 mg/kg/hour to at least 10 mg/kg/hour, all for from about 1 to about 120 hours and especially 24 to 96 hours. A preloading bolus of from about 0.1 mg/kg to about 10 mg/kg or more may also be administered to achieve adequate steady state levels. The maximum total dose is not expected to exceed about 2 g/day for a 40 to 80 kg human patient.

[00309] For the prevention and/or treatment of long-term conditions, such as, e.g., arthritis, diabetes, multiple sclerosis (and the animal model thereof, EAE), rheumatoid arthritis (and the animal model thereof, CIA), psoriasis, or asthma, the regimen for treatment usually stretches over many months or years, so oral dosing is preferred for patient convenience and tolerance. With oral dosing, one to five and especially two to four and typically three oral doses per day are representative regimens. Using these dosing patterns, each dose provides from about 0.01 to about 20 mg/kg of the compound of the invention, with preferred doses each providing from about 0.1 to about 10 mg/kg and especially about 1 to about 5 mg/kg.

[00310] Transdermal doses are generally selected to provide similar or lower blood levels than are achieved using injection doses. Modes of administration suitable for mucosal sites are also envisioned herein and include without limitation: intra-anal swabs, enemas, intranasal sprays, and aerosolized or vaporized compounds and/or compositions for delivery to the lung mucosa. One of skill in the art would choose an appropriate delivery mode/s based on a variety of parameters, including the organ or tissue site in a patient with a disease or condition that is most severely affected by the disease or condition. A skilled practitioner could, for example, treat a patient afflicted with an inflammatory bowel disease (IBD) with a therapeutic regimen that included delivery of the compounds or compositions of the invention using an enema for direct delivery to the bowel.

[00311] When used to prevent the onset of an inflammatory condition or autoimmune disorder, the compounds of this invention will be administered to a patient at risk for developing the condition or disorder, typically on the advice and under the supervision of a physician, at the dosage levels described above. Patients at risk for developing a particular condition generally include those that have a family history of the condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the condition.

[00312] The compounds of this invention can be administered as the sole active agent or they can be administered in combination with other agents, including other compounds that demonstrate the same or a similar therapeutic activity and are determined to be safe and efficacious for such combined administration.

GENERAL SYNTHETIC PROCEDURES

[00313] The amido compounds of this invention may be purchased from various commercial sources or can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

[00314] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and P. G. M. Wuts, *Protecting Groups in Organic Synthesis*, Second Edition, Wiley, New York, 1991, and references cited therein.

[00315] The compounds of the invention may be prepared from known or commercially available starting materials and reagents by one skilled in the art of organic synthesis.

General Materials and Methods:

[00316] All commercially available reagents and solvents were purchased and used without further purification. All microwave reactions were carried out in a sealed microwave vial equipped with a magnetic stir bar and heated in a Biotage Initiator Microwave Synthesizer. HPLC purification was performed using a Waters semi-preparative HPLC equipped with a Phenomenex Luna[®] C18 reverse phase (5 micron, 30 x 75 mm) column (unless state otherwise) having a flow rate of 45 mL/min. The mobile phase was a mixture of acetonitrile and H₂O each containing 0.1% trifluoroacetic acid. ¹H spectra were recorded using either an Inova 400 MHz spectrometer (Varian) or an Inova 300 MHz spectrometer (Varian). Two LCMS methods were used to analyze samples' purity. Method 1: Agilent 1200 series LC/MS equipped with a Zorbax[™] Eclipse XDB-C18 reverse phase (5 micron, 4.6 x 150 mm) column having a flow rate of 1.1 mL/min. The mobile phase was a mixture of acetonitrile and H₂O each containing 0.05% trifluoroacetic acid. A gradient of 5% to 100% acetonitrile over 8 minutes was used during analytical analysis. Method 2: Acquity HPLC equipped with a Waters BEH C18, 1.7 micron, 2.1 x 50 mm column; Column Temperature: 45 degrees C; Flow: 0.5mL/min; Solvent A: 0.05% TFA in Water; Solvent B: 0.025% TFA in Acetonitrile; Gradient: 2% to 100% Solvent B over 1.3 minutes; Run Time- 3 min. High-resolution mass spectroscopy measurements were performed on a Agilent 6210 Electrospray TOF mass spectrometer.


[00317] The following general procedures were used to synthesize compounds having different but analogous structures. One skilled in the art of synthesis will recognize how to modify these general procedures if necessary to accomplish the desired transformations.

Representative Synthetic Methods

Method A

[00318] The representative hydroxy compounds of the invention can be prepared using the general synthetic pathway depicted in Scheme 1.

Scheme 1



The following reaction conditions were used for step 1:

- (1) TFA, 60-100 °C, 2-16 h
or (2) p-toluenesulfonic acid, 125 °C, 2h

The following reaction conditions were used for step 2:

- (1) R^5R^6NH , 60-80 °C, DMA or THF, 2-16 h
or (2) R^5R^6NH , Me_3Al , Toluene/DCE, 50 °C, 4-12 h

and wherein R^3 , R^4 , R^5 , R^6 , $n1$ and $n2$ are as described herein.

Step 1:

[00319] A mixture of phenol (1, 0.2 mmol) and cinnamic acid (2, 0.2 mmol) in TFA (2 mL) was heated at 60-100 °C for 2-16 h. Upon completion, TFA was removed using a Genevac evaporator and the residue was dissolved in DCM (2 mL), washed with saturated $NaHCO_3$ (2 mL). After removing solvent, the intermediate compound 3 was obtained. The intermediate compound 3 may be prepared using the following procedure.


[00320] A mixture of (1, 0.2 mmol), cinnamic acid (2, 0.2 mmol) and p-toluenesulfonic acid (0.2 mmol) was heated at 125 °C for 2 h. The reaction mixture was cooled to room temperature and dissolved in DCM (2 mL), washed with NaOH (1 M, 1 mL). After removing solvent, the intermediate compound 3 was obtained and used for next step without further purification.

Step 2:

[00321] A mixture of 3 (0.2 mmol) and amine (R^5R^6NH , 0.3 mmol) in DMA or THF (2 mL) was heated at 60-80 °C for 2-16 h. Upon completion, the mixture was cooled to room temperature. The desired product 4 was obtained by HPLC purification. The compound 4 may be prepared using the following procedure.

[00322] To an 8 mL-vial, amine (R^5R^6NH , 0.3 mmol) was added. The vial was capped with a Teflon cap, and then Me_3Al (0.4 mL, 1M in heptane) was added. The resulting mixture was shaken at room temperature for 1 h. This was followed by addition of 3 (0.2 mmol, dissolved in 1 mL dry toluene/or DCE). The resulting mixture was heated at 50 °C for 12 h. The reaction mixture was cooled to room temperature and concentrated in a GeneVac. The residue was dissolved in DCM (2 mL), and then $Na_2SO_4 \cdot 10H_2O$ (0.2 mmol, 32 mg) was added. The suspension was vortexed and centrifuged, the clean solution was separated and concentrated. The crude product was purified by HPLC to afford 4.

Method B




Reaction conditions: (i) $\text{BF}_3\text{Et}_2\text{O}$, 0°C - r.t. 1-2 h; (ii) LiOH , $\text{THF}/\text{H}_2\text{O}/\text{MeOH}$, MW, 150°C , 1 h; (iii) DMC , $\text{R}^5\text{R}^6\text{NH}$, Hunig base, CH_2Cl_2

and wherein R^3 , R^4 , R^5 , R^6 , n_1 and n_2 are as described herein.

General procedure

[00323] To a solution of **5** (1 mmol) and (1-methoxy-2-methylprop-1-en-1-yloxy)trimethylsilane (1.5 mmol) in 10 mL of DCM at 0°C was added $\text{BF}_3\text{Et}_2\text{O}$ (1.5 mmol) with stirring. The mixture was warmed to r.t. and stirring was continued for 1-2 h. Upon completion, 20 mL DCM was added and the organic layer was washed with sat Na_2CO_3 solution (10 mL) and water (10 mL), dried over MgSO_4 and concentrated. The residue was purified by column chromatography over silica-gel to give **6**. A solution of **6** (0.5 mmol) and LiOH (5 mmol) in a mixture of solvents (10 mL THF, 5 mL MeOH and 5 mL water) was heated in a microwave at 150°C for 1 h. Upon completion, the solvent was removed. The residue was dissolved in 10 mL of water and the solution was acidified by 1 M HCl to $\text{pH} = 2$. The resulting mixture was extracted with DCM (3 x 30 mL). The combined organic layers was dried over MgSO_4 , filtered and concentrated to give acid **7**. To a solution of acid **7** (0.3 mmol) and Hunig base (1 mmol) in DCM (10 mL) was added 2-chloro-1,3-dimethylimidazolinium chloride (1.5 mmol) at room temperature. After stirring for 10 min, a solution of amine (0.6 mmol $\text{R}_3\text{R}_4\text{NH}$ in DCM or DMA) was added. The resulted mixture was stirred for 4-12 h. After concentrated, the residue was purified by HPLC to yield the desired **8**.

Method C



Reaction conditions: (i) TFA, CH_2Cl_2 , $Pd(OAc)_2$, 40 °C, 8 h; (ii) R^5R^6NH , MeOH, HCO_2NH_4 , 10% Pd/C, 50 °C, 8 h and wherein R^3 , R^4 , R^5 , R^6 , $n1$ and $n2$ are as described herein.


General Procedure:

[00324] Compound 2 was either used without purification from commercial sources or synthesized following the literature procedure (Xie, L. et al.; *J. Med. Chem.* **1999**, 42, 2662.)

[00325] A solution of 2 (1 mmol) in CH_2Cl_2 (0.9 mL) was treated with phenol 1 (1 mmol), TFA (2.7 mL) and $Pd(OAc)_2$ (15 mg, 0.069 mmol), and stirred at 40 °C for 8 h. The reaction mixture was concentrated to dryness using the Genevac evaporator and used crude in the next step. * Crude 9 was dissolved in MeOH (1 mL), treated with R^5R^6NH (2 mmol), 10% Pd/C (8 mg, 0.1 mmol) and ammonium formate (67 mg, 1 mmol) and heated to 50 °C for 8 h. The reaction mixture was diluted with MeOH, filtered through a solid supported thiol column, and concentrated under reduced pressure. The material was purified by HPLC to yield compound 4.

[00326] *The degree of oxidation to 9 was substrate dependent and sometimes the primary product was lactone 3 as determined by LCMS. If the level of oxidation was < 20%, amide 4 was synthesized following the same conditions described in Method A.

Method D




Reaction Conditions: (i) $Pd(OAc)_2$, BIPY, AcOH, H_2O , THF, 60 °C, 8 h; (ii) R^5R^6NH , DMA, 80 °C, 8 h and wherein R^3 , R^4 , R^5 , R^6 , $n1$ and $n2$ are as described herein.

General Procedure

[00327] A suspension of coumarin 10 (0.15 mmol), boronic acid 11 (0.4 mmol) BIPY (10 mg, 0.064 mmol), and $Pd(OAc)_2$ (7 mg, 0.03 mmol) in AcOH (0.6 mL), THF (0.2 mL) and H_2O (0.1 mL) was heated to 60 °C for 8 h and concentrated to dryness in the Genevac evaporator to

afford **3** which was used without purification in the following step. Crude lactone **3** was converted to amide **4** following the same protocol as Method A (NHR5R6, DMA, 80 °C) and purified with HPLC to afford product **4**.

Method E




Reaction Conditions: (i) Pd(OAc)₂, BIPY, AcOH, H₂O, THF, 60 °C, 8 h; (ii) R⁵R⁶NH, 2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidine, 70 °C, 8 h and wherein R³, R⁴, R⁵, R⁶, n1 and n2 are as described herein.

General Procedure:

[00328] A suspension of cinnamic ester **2** (0.15 mmol), boronic acid **11** (0.4 mmol) BIPY (10 mg, 0.064 mmol), and Pd(OAc)₂ (7 mg, 0.03 mmol) in AcOH (0.6 mL), THF (0.2 mL) and H₂O (0.1 mL) was heated to 60° C for 8 h and concentrated to dryness in the Genevac evaporator to afford **12** which was used without purification in the following step. Crude **12** was treated with 2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidine (0.18 mmol) and R⁵R⁶NH and heated to 70 °C for 8 h. The reaction mixture was purified by HPLC to afford **13**.

Method F




and wherein R³, R⁴, R⁵, R⁶, R^{7a}, n1 and n2 are as described herein.

General Procedure:

[00329] A mixture of **4** (0.1 mmol) and NaH (0.2 mmol) was dissolved in dry THF (2 mL). After stirring at room temperature for 0.5 h, alkyl halide (0.4 mmol) was added. The resulting mixture was heated at 60 °C for 2-8 h. The solution was cooled to room temperature. A couple drops of water were added and the mixture was purified by HPLC to give compound **14**.

Method G



Reaction Conditions: (i) TBAB, K_3PO_4 , $\text{Pd}(\text{dppf})_2\text{Cl}_2$ (ii) Pd/H_2 ; (iii) $\text{R}^5\text{R}^6\text{NH}$, 60 °C, THF

and wherein R^3 , R^4 , R^5 , R^6 , R^{7a} , n1 and n2 are as described herein.

General procedure:

Step 1

[00330] A suspension of 4-(trifluoromethylsulfonyloxy) coumarin **Z01** (0.3 mmol, 1.0 eq.), boronic acid **11** (0.33 mmol, 1.1 eq.), potassium phosphate (3.0 eq.), tetrabutylammoniumbromide (0.1 eq.), and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.1 eq.) in acetonitrile/ H_2O (3.5 mL:0.5 mL), was refluxed under nitrogen until the substrate was completely consumed (12 h, monitored by LCMS or TLC). The reaction mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous Na_2SO_4 , and the solvent was removed under reduced pressure. The residue was purified by TLC (EtOAc/petroleum=3:2) or by prep-HPLC, to afford the intermediate **B0XZ01-1**.

Step 2

[00331] The intermediate **B0XZ01-1** (1.0 eq.) was dissolved in 5 mL EtOAc, Pd/C (ca. 7-10 mg, 20%) was added and the mixture was stirred at rt. for 12 hours under H_2 balloon. The reaction was monitored by LCMS. The stirring is continued until the double bond was reduced completely. The catalyst Pd/C was filtered off, and the solvent was removed under reduced pressure to afford the crude **B0XZ01** which was used as such for the next step.


Step 3

The intermediate **B0XZ01** (1.0 eq.) and amine ($\text{R}^5\text{R}^6\text{NH}$, 1.1 eq.) were dissolved in 2.5 mL of THF, the reaction mixture was stirred at 60 °C for 5 hours. The solvent was removed under

reduced pressure to afford the crude product **13**. The crude product was then purified by prep-HPLC, to afford the desired product **13**.

Synthesis of the Heteroaryl Compounds of the Invention

[00332] The representative heteroaryl compounds of the invention can be prepared following the general synthetic pathways and synthetic methods described above; and replacing the group



with the appropriate HET¹ group.

Representative Examples:

Compound 83 (Method D)

[00333] 1-(3,5-Dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(3-(methylsulfonyl)phenyl)propan-1-one (Compound 83, Table 1)

[00334] Prepared by method D: ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.54 (d, *J*=9.19 Hz, 1 H) 7.77 (s, 1 H) 7.64 - 7.68 (m, 1 H) 7.51 - 7.56 (m, 1 H) 7.47 (t, *J*=7.73 Hz, 1 H) 5.99 - 6.06 (m, 2 H) 5.02 - 5.10 (m, 1 H) 4.31 (d, *J*=13.11 Hz, 1 H) 3.74 - 3.82 (m, 1 H) 3.67 (d, *J*=1.76 Hz, 3 H) 3.65 (s, 3 H) 3.35 - 3.47 (m, 1 H) 3.19 - 3.26 (m, 1 H) 3.12 - 3.15 (m, 3 H) 2.99 - 3.10 (m, 1 H) 2.83 - 2.95 (m, 1 H) 1.84 - 1.93 (m, 1 H) 1.63 - 1.75 (m, 1 H) 1.13 - 1.35 (m, 2 H) 0.69 - 0.90 (m, 6 H); LCMS: (electrospray +ve), *m/z* 476.2 (MH)⁺; HPLC: *t*_R = 5.63 min, UV₂₅₄ = 99%.

Compound 99 (Method D)

[00335] 4-(3-(3,5-Dimethylpiperidin-1-yl)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-oxopropyl)benzoic acid (Compound 99, Table 1)

[00336] ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.57 - 0.74 (m, 1 H) 0.73 - 0.92 (m, 6 H) 1.06 - 1.48 (m, 2 H) 1.57 - 1.77 (m, 1 H) 1.88 (t, *J*=12.0 Hz, 1 H) 2.85 - 3.37 (m, 2 H) 3.65 (s, 6 H) 3.70 - 3.86 (m, 1 H) 4.30 (d, *J*=12.5 Hz, 1 H) 5.00 (t, *J*=7.1 Hz, 1 H) 5.98-6.04 (m, 2 H) 7.31 (dd, *J*=7.6, 5.3 Hz, 2 H) 7.76 (d, *J*=8.2 Hz, 2 H) 9.44 (br. s., 1 H); LC-MS: LCMS: (electrospray +ve), *m/z* 442.3 (MH)⁺; *t*_R = 4.49 min, UV₂₅₄ = 95%.

Compound 100 (Method D)

[00337] 3-(4-Acetylphenyl)-1-(3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one (Compound 100, Table 1)

[00338] Prepared by method D: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 9.42 - 9.47 (m, 1 H) 7.78 (d, $J=8.22$ Hz, 2 H) 7.33 (d, $J=8.22$ Hz, 2 H) 5.98 - 6.05 (m, 2 H) 4.99 - 5.04 (m, 1 H) 4.31 (d, $J=15.06$ Hz, 1 H) 3.74 - 3.80 (m, 1 H) 3.62 - 3.70 (m, 6 H) 3.14 - 3.25 (m, 1 H) 3.09 (d, $J=9.59$ Hz, 1 H) 2.96 (d, $J=9.00$ Hz, 1 H) 2.55 (d, $J=3.91$ Hz, 1 H) 2.52 (s, 3 H) 1.85 - 1.94 (m, 1 H) 1.63 - 1.76 (m, 1 H) 1.20 - 1.28 (m, 2 H) 0.64 - 0.90 (m, 6 H); LCMS: (electrospray +ve), m/z 440.2 (MH) $^+$; HPLC: t_R = 5.92 min, UV_{254} = 90%.

Compound 101 (Method D)

[00339] 3-(3-(3,5-Dimethylpiperidin-1-yl)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-oxopropyl)benzoic acid (Compound 101, Table 1)

[00340] Prepared by method D: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 12.73 (br. s., 1 H) 9.44 - 9.48 (m, 1 H) 7.82 - 7.89 (m, 1 H) 7.65 (d, $J=7.63$ Hz, 1 H) 7.46 (t, $J=9.68$ Hz, 1 H) 7.27 - 7.33 (m, 1 H) 6.00 - 6.04 (m, 2 H) 4.97 - 5.03 (m, 1 H) 4.31 (d, $J=15.45$ Hz, 1 H) 3.73 - 3.81 (m, 1 H) 3.67 (d, $J=4.69$ Hz, 3 H) 3.65 (s, 3 H) 3.12 - 3.24 (m, 1 H) 2.98 (dd, $J=13.79, 7.92$ Hz, 1 H) 2.76 - 2.89 (m, 1 H) 2.37 - 2.47 (m, 1 H) 1.84 - 1.92 (m, 1 H) 1.62 - 1.74 (m, 1 H) 1.24 (s, 2 H) 0.71 - 0.91 (m, 6 H); LCMS: (electrospray +ve), m/z 442.2 (MH) $^+$; HPLC: t_R = 5.51 min, UV_{254} = 98%.

Compound 106 (Method D)

[00341] 1-(3,5-Dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(pyridin-3-yl)propan-1-one (Compound 106, Table 1)

[00342] ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 9.46 - 9.49 (m, 1 H) 7.15 (d, $J=5.09$ Hz, 1 H) 6.79 - 6.83 (m, 1 H) 6.74 - 6.78 (m, 1 H) 6.03 (dq, $J=4.35, 2.20$ Hz, 2 H) 5.13 - 5.24 (m, 1 H) 4.33 (d, $J=12.13$ Hz, 1 H) 3.72 - 3.79 (m, 1 H) 3.70 (d, $J=5.48$ Hz, 3 H) 3.66 (s, 3 H) 3.12 (d, $J=7.04$ Hz, 1 H) 2.82 - 3.02 (m, 1 H) 2.41 (td, $J=12.33, 7.04$ Hz, 1 H) 1.84 - 1.92 (m, 1 H) 1.62 -

1.72 (m, 1 H) 1.11 - 1.37 (m, 3 H) 0.63 - 0.84 (m, 6 H); LC-MS: (electrospray +ve), m/z 399.2 (MH)⁺ t_R = 4.31 min, UV₂₅₄ = 90%.

Compound 107 (Method A)

[00343] 1-(3,5-Dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(thiophen-2-yl)propan-1-one (Compound 107, Table 1)

[00344] ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.46 - 9.49 (m, 1 H) 7.15 (d, J =5.09 Hz, 1 H) 6.79 - 6.83 (m, 1 H) 6.74 - 6.78 (m, 1 H) 6.03 (dq, J =4.35, 2.20 Hz, 2 H) 5.13 - 5.24 (m, 1 H) 4.33 (d, J =12.13 Hz, 1 H) 3.72 - 3.79 (m, 1 H) 3.70 (d, J =5.48 Hz, 3 H) 3.66 (s, 3 H) 3.12 (d, J =7.04 Hz, 1 H) 2.82 - 3.02 (m, 1 H) 2.41 (td, J =12.33, 7.04 Hz, 1 H) 1.84 - 1.92 (m, 1 H) 1.62 - 1.72 (m, 1 H) 1.11 - 1.37 (m, 3 H) 0.63 - 0.84 (m, 6 H); LC-MS: (electrospray +ve), m/z 404.2 (MH)⁺ t_R = 6.13 min, UV₂₅₄ = 98%.


Compound 108 (Method D)

[00345] 1-(3,5-Dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(pyridin-4-yl)propan-1-one (Compound 108, Table 1)

[00346] ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.49 (d, J =5.87 Hz, 1 H) 8.34 (d, J =6.26 Hz, 2 H) 7.14 (d, J =5.09 Hz, 2 H) 5.97 - 6.06 (m, 2 H) 4.91 - 4.98 (m, 1 H) 4.32 (d, J =16.82 Hz, 1 H) 3.73 - 3.84 (m, 1 H) 3.66 (s, 6 H) 3.17 - 3.27 (m, 1 H) 2.91 - 3.07 (m, 2 H) 2.36 - 2.46 (m, 1 H) 1.86 - 1.94 (m, 1 H) 1.62 - 1.77 (m, 1 H) 1.42 - 1.51 (m, 2 H) 0.77 - 0.90 (m, 6 H); LC-MS: LCMS: (electrospray +ve), m/z 399.2 (MH)⁺; t_R = 4.35 min, UV₂₅₄ = 99%.

Compound 141 (Method E)

[00347] 3-(4-(1H-1,2,4-Triazol-1-yl)phenyl)-3-(benzo[d][1,3]dioxol-5-yl)-1-(3,5-dimethylpiperidin-1-yl)propan-1-one 13m (NCGC00242637, **141**)




Reaction Conditions: (i) Pd(OAc)₂, BIPY, AcOH, H₂O, THF, 60 °C, 8 h; (ii) 3,5-dimethylpiperidine, 2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidine, 70 °C, 8 h

[00348] Prepared by method E: A suspension of cinnamic methyl ester (**2m**, 224 mg, 0.97 mmol), boronic acid **11a** (315 mg, 1.89 mmol) BIPY (30 mg, 0.192 mmol), and Pd(OAc)₂ (30 mg, 0.134 mmol) in AcOH (1.5 mL), THF (0.5 mL) and H₂O (0.25 mL) was heated to 60 °C for 8 h and concentrated to dryness in the Genevac evaporator to afford **12m** which was used without purification in the following step. The crude methyl ester was treated with 3,5-dimethylpiperidine (1.34 mL, 9.88 mmol) and 2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidine (0.134 g, 0.96 mmol) and heated to 70 °C for 8 h, the reaction mixture was purified by HPLC to afford the amide **13m**. LCMS: (electrospray +ve), *m/z* 433.2 (MH)⁺; HPLC: *t_R* = 5.87 min, UV₂₅₄ = 99%.

Compound 201 (Method D)

[00349] 4-(3-(3,5-*cis*-Dimethylpiperidin-1-yl)-3-oxo-1-(2,4,6-trimethoxyphenyl)-propyl)benzoic acid (NCGC00249676)




[00350] To a solution of Compound 202 (20 mg, 0.046 mmol) in 2 mL of DMF was added potassium carbonate (500 mg) and iodomethane (64 mg, 0.452 mmol). The mixture was heated at 60 °C for 8 h. The solvent was removed and the residue was dissolved in a mixed solvent (2 mL THF, 1 mL MeOH and 1 mL water). To this solution was added 4 equiv of LiOH and the mixture was stirred overnight. After removed solvent, 2 mL of water was added and the solution was

acidified to pH 2 using 1.0 M HCl. The aqueous layer was extracted with 2 x 15 mL DCM. Combined organic layer and dried over MgSO₄, filtered and concentrated. The crude product was purified *via* column chromatography on SiO₂ (ethyl acetate (contain 1% acetic acid)/hexane 30% - 80%) to give Compound 201 (15 mg, 73%) as a white solid.

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.62 - 0.78 (m, 1 H), 0.78-0.90 (m, 6 H), 1.10-1.55 (m, 2 H), 1.60-1.70 (m, 1 H), 1.82-1.95 (m, 1 H), 2.45-2.49 (m, 1H), 2.90 - 3.25 (m, 2 H), 3.71 (s, 3 H), 3.72 (s, 3 H), 3.76 (s, 3 H), 3.67 - 3.84 (m, 1 H), 4.31-4.34 (m, 1 H), 5.08 (t, *J*=7.4 Hz, 1 H), 6.22 (s, 1 H), 6.23 (s, 1 H), 7.27-7.33 (m, 2 H), 7.79 (d, *J*=8.6 Hz, 2 H), 12.64 (br. s., 1H); LC/MS: (electrospray +ve), *m/z* 456.2 (MH)⁺, *t*_R = 5.98 min, UV₂₅₄ = 100%.

Compound 202 (Method D)

[00351] 4-(3-(3,5-*cis*-Dimethylpiperidin-1-yl)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-oxopropyl)benzoic acid (NCGC00249675)



[00352] A suspension of 5,7-dimethoxy-2H-chromen-2-one (155 mg, 0.75 mmol), 4-boronobenzoic acid (622 mg, 3.75 mmol), 2,2'-bipyridine (93 mg, 0.60 mmol), and Pd(OAc)₂ (33 mg, 0.15 mmol) in dimethylacetamide (4.0 mL) and acetic acid (1.0 mL) was heated at 110 °C for 24 h. The reaction was concentrated under reduced pressure and the residue was dissolved in a mixture of ethyl acetate/dichloromethane (1 to 1, 20 mL). The solution was filtered through a plug of silica gel followed by flushing with ethyl acetate (contain 0.5% acetic acid). After evaporation of the solvent in vacuo, the crude product was dissolved in 4 mL of DMA followed by addition of *cis*-dimethylpiperidine (170 mg, 1.5 mmol). The mixture was heated at 80 °C for 6 h. The crude product was purified *via* column chromatography on SiO₂ (ethyl acetate (contain 1% acetic acid)/hexane 30% - 80%) to give the pure Compound 202 as a white solid (28 mg, 8%).


¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.56 - 0.72 (m, 1 H), 0.78 (br. s., 6 H), 1.17 (br. s., 2 H) 1.65 (br. s., 1 H), 1.86 (t, *J*=11.74 Hz, 1 H), 2.31-2.48 (m, 1H), 2.86 - 3.20 (m, 2 H), 3.63 (s, 6 H), 3.68 - 3.83 (m, 1 H), 4.24-4.34 (m, 1 H), 4.98 (t, *J*=6.26 Hz, 1 H), 6.00 (s, 2 H), 7.23-7.33 (m,

2 H), 7.74 (d, $J=7.04$ Hz, 2 H), 9.43 (br. s., 1 H), 12.55 (br. s., 1H); LC/MS: (electrospray +ve), m/z 442.3 (MH)⁺, t_R = 5.60 min, UV₂₅₄ = >95%.

Compound 203 (Method A)

[00353] 1-(3,5-Dimethylpiperidin-1-yl)-3-(4,6-dimethoxy-2-hydroxy-phenyl)-3-(4-methylimidazol-4-yl)propan-1-one (A03Y01C01)

Scheme1:



Step 1:

[00354] The starting imidazole derivative (X03, 500 mg, 1.0 eq.) and malonic acid (472.5mg, 1.0 eq.) were dissolved in 3.5 mL of pyridine. 3 Drops of piperidine were added and the mixture was heated at 100 °C under nitrogen for 5 hours. The reaction was monitored by LCMS and TLC. The reaction solution was diluted with water, the pH was adjusted to 5 with 1M HCl, and then extracted twice with ethyl acetate (2X10mL). The organic layers were combined, dried with anhydrous sodium sulfate, filtered and concentrated to obtain the crude product A03, which was purified by column chromatography (EtOAc:Petroleum=2:1) to get pure A03 (400 mg).

Step 2:

[00355] The intermediate A03 (300 mg, 1.0 eq.) and 3,5-dimethoxyphenol (Y01, 304 mg, 1.0 eq.) were dissolved in 3mL of TFA/DCE, and the mixture was stirred at 80 °C under microwave irradiation for 45 minutes. The reaction mixture was neutralized with aqueous NaHCO₃ and extracted with CH₂Cl₂. The organic layer was dried with anhydrous sodium sulfate, filtered and concentrated to obtain the crude product A03Y01 (300mg), which was used as such for the next step.

Step 3:

[00356] The intermediate A03Y01 (300 mg, 1.0 eq.) and 3,5-dimethylpiperidine (C01, 130 mg, 1.1 eq.) were dissolved in 3mL of THF, the reaction mixture was stirred at 60 °C for 12 hours, and the solvent was evaporated under reduced pressure to get the crude product A03Y01C01. The crude product was then dissolved in 2.5 mL MeOH, and purified by pre-HPLC to get pure 1-(3,5-dimethylpiperidin-1-yl)-3-(4,6-dimethoxy-2-hydroxy-phenyl)-3-(4-methylimidazol-4-yl)propan-1-one (A03Y01C01, 57.6 mg), QC: 95.87%.


¹H NMR (400 MHz, CDCl₃) δ 6.53 (s, 1H), 6.20 (dd, J = 5.1, 2.4 Hz, 1H), 6.03 (d, J = 2.3 Hz, 1H), 5.07 – 4.96 (m, 1H), 4.49 (d, J = 12.8 Hz, 1H), 3.75 (d, J = 3.1 Hz, 6H), 3.43 (dd, J = 14.6, 10.0 Hz, 1H), 3.24 (dd, J = 14.6, 9.1 Hz, 1H), 3.01 – 2.66 (m, 1H), 2.30 (d, J = 6.4 Hz, 3H), 1.89 (dd, J = 23.3, 11.6 Hz, 1H), 1.74 (d, J = 10.3 Hz, 1H), 1.36 (ddd, J = 47.7, 28.9, 15.8 Hz, 3H), 0.88 – 0.82 (m, 6H), 0.68 (dd, J = 24.5, 12.1 Hz, 1H).

MS(MeOH): [M+1]⁺ 402.1, 384.1, 289.0, 212.2, 114.0.

Compound 204 (Method A)

[00357] 1-(3,5-Dimethylpiperidin-1-yl)-3-(4,6-dimethoxy-2-hydroxy-phenyl)-3-(pyrazin-2-yl)propan-1-one (A04Y01C01)

Scheme2:



Step 1:

[00358] The starting pyrazine derivative (X04, 500 mg, 1.0 eq.) and malonic acid (481.3 mg, 1.0 eq.) were dissolved in 3.5 mL of pyridine, 3 drops of piperidine were added, and the

mixture was heated at 100 °C under nitrogen for 5 hours. The reaction was monitored by LCMS and TLC. The reaction solution was diluted with water, the pH was adjusted to 5 with 1M HCl, and then extracted twice with ethyl acetate (2X10mL). The organic layers were combined, dried with anhydrous sodium sulfate, filtered and concentrated to obtain the crude product A04, which was then purified by column chromatography (EtOAc:Petroleum=1:1) to get pure A04 (200 mg).
Step 2:

[00359] The intermediate A04 (200 mg, 1.0 eq.) and 3,5-dimethoxyphenol (205.37mg, 1.0 eq.) were dissolved in 3mL of TFA/DCE, and the mixture was stirred at 80 °C under microwave irradiation for 45 minutes. The reaction mixture was neutralized with aqueous NaHCO₃ and extracted with CH₂Cl₂. The organic layer was dried with anhydrous sodium sulfate, filtered and concentrated to obtain the crude product A04Y01 (100 mg)), which was used as such for the next step.

Step 3:

[00360] The intermediate A03Y01 (100 mg, 1.0 eq.) and 3,5-dimethylpiperidine (C01, 43.5 mg, 1.1 eq.) were dissolved in 3mL of THF, the reaction mixture was stirred at 60 °C for 12 hours, and the solvent was evaporated under reduced pressure to get the crude product A04Y01C01, which was purified by pre-HPLC to yield pure 1-(3,5-dimethylpiperidin-1-yl)-3-(4,6-dimethoxy-2-hydroxy-phenyl)-3-(pyrazin-2-yl)propan-1-one (A04Y01C01, 6.4mg), QC: 92.12%.


¹H NMR (400 MHz, CDCl₃) δ 8.43 (s, 1H), 8.30 (d, J = 2.1 Hz, 1H), 8.21 (d, J = 26.9 Hz, 1H), 7.28 (s, 1H), 6.02 (s, 2H), 4.56 (dd, J = 15.2, 9.5 Hz, 2H), 3.64 – 3.57 (m, 6H), 3.22 – 3.08 (m, 1H), 2.17 (dd, J = 13.3, 9.8 Hz, 1H), 2.01 – 1.88 (m, 2H), 1.57 (d, J = 12.0 Hz, 1H), 1.27 (s, 3H), 0.85 (t, J = 6.0 Hz, 3H), 0.73 (d, J = 6.5 Hz, 1H), 0.46 (s, 2H).

MS(MeOH): [M+1]⁺: 400.1, 347.1, 287.1, 259.1.

Compound 205 (Method A)

[00361] 1-(3,5-Dimethylpiperidin-1-yl)-3-(4,6-dimethoxy-2-hydroxy-phenyl)-3-(benzothiazol-2-yl)propan-1-one (A05Y01C01)

Scheme 3:



Step 1:

[00362] The benzothiazole derivative (X05, 300 mg, 1.0 eq.) and malonic acid (191.3 mg, 1.0 eq.) were dissolved in 3.5 mL pyridine, 3 drops of piperidine were added and the mixture was heated at 100 °C under nitrogen for 5 hours, The reaction was monitored by LCMS and TLC. The reaction solution was diluted with water, the pH was adjusted to 5 with 1M HCl, and extracted twice with ethyl acetate (2X10mL). The organic layers were combined, dried with anhydrous sodium sulfate, filtered and concentrated to obtain the crude product A05, which was purified by column chromatography (EtOAc:Petroleum =1:1) to get pure A05 (100 mg).

Step 2:

[00363] The intermediate A05 (100 mg, 1.0 eq.) and 3,5-dimethoxyphenol (Y01, 75.12 mg, 1.0 eq.) were dissolved in 3 mL of TFA/DCE, and the mixture was stirred at 80 °C under microwave irradiation for 45 minutes. The reaction mixture was then neutralized with aqueous NaHCO₃ and extracted with CH₂Cl₂. The organic layer was dried with anhydrous sodium sulfate, filtered and concentrated to obtain the crude product A05Y01 (65 mg), which was used as such for the next step.

Step 3:

[00364] The intermediate A05Y01 (65 mg, 1.0 eq.) and 3,5-dimethylpiperidine (C01, 23.7mg, 1.1 eq.) were dissolved in 3 mL THF, the reaction mixture was stirred at 60 °C for 12 hours, and the solvent was evaporated under reduced pressure to get crude product A05Y01C01, which was purified by pre-HPLC to give the pure titled compound, A05Y01C01 (6.5mg), QC: 100%.

¹H NMR (400 MHz, CDCl₃) δ 7.91 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.35 (dt, J = 29.0, 7.4 Hz, 2H), 5.94 (d, J = 11.2 Hz, 2H), 4.68 – 4.54 (m, 2H), 3.95 (dd, J = 14.2, 6.3 Hz, 1H), 3.49 (t, J = 5.7 Hz, 6H), 2.19 (dd, J = 13.2, 9.6 Hz, 1H), 2.04 – 1.89 (m, 2H), 1.77 (d, J = 13.2

Hz, 1H), 1.59 (d, J = 10.9 Hz, 1H), 1.36 – 1.24 (m, 3H), 0.87 (dd, J = 15.7, 7.9 Hz, 3H), 0.75 (d, J = 6.6 Hz, 1H), 0.49 (s, 2H).


MS(MeOH): [M+1]⁺: 455.1, 342.0.

Compound 206 (Method G)

[00365] 1-(3,5-Dimethylpiperidin-1-yl)-3-(4,6-dimethoxy-2-hydroxy-phenyl)-3-(2-methoxypyrid-5-yl)propan-1-one (B03X01C01)

A. Synthesis of the starting material – Z01

Scheme 4:



Step 1

[00366] 2,4-Dimethoxy-6-hydroxybenzaldehyde (**1**, 5g, 1.0 eq.) was dissolved in 5 mL of dimethyl carbonate, and NaH (1.2 g, 1.2 eq.) was added. The reaction mixture was refluxed at 135 °C for 30 mins, and then filtered to afford filter cake. The filter cake was dissolved in water, the pH was adjusted to 5-6 with aqueous 2M HCl to get a precipitate. The precipitated solid was collected by filtration, and was redissolved in EtOAc. The solution was dried over anhydrous Na₂SO₄, and filtered and the solvent was removed under reduced pressure to get the crude product **3**, which was used as such for the next step.


Step 2

[00367] To a solution of the intermediate compound **3** (4.8g, 1.0 eq.) and triethylamine (4.8 mL, 1.5 eq.) in 60 mL of dry dichloromethane at 0 °C under nitrogen was added trifluoromethanesulfonic anhydride (15 mL, 1.1 eq.) slowly. The reaction solution was allowed to warm to room temperature and stirred for 1 h. The reaction mixture was washed with 10 percent aqueous potassium carbonate (2X50 mL) and then aqueous 2M HCl (2X50 mL), and the organic

layer was dried and the solvent was removed in vacuo to give the intermediate compound Z01 as a yellow solid. It was then purified by column chromatography (petroleum/EtOAc=30:1) to afford pure Z01 as white solid (3g).

B. Preparation of Compound 206 (B03X01C01)

Scheme 5:



Step 1

[00368] A suspension of 4-(trifluoromethylsulfonyloxy) coumarin (100 mg, 1.0 eq.), boronic acid derivative B03 (43.17mg,1.1eq.), potassium phosphate (179.6 mg, 3.0 eq.), tetrabutylammoniumbromid (9 mg, 0.1 eq.), and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (2.06 mg, 0.1 eq.) in acetonitrile/H₂O (3.5 mL:0.5mL), was refluxed under nitrogen until the substrate was completely consumed (12 h, monitored by LCMS or TLC). The reaction mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over anhydrous Na₂SO₄, and the solvent was distilled under reduced pressure. The residue was purified by TLC (EtOAc/petroleum=3:2) or by prep-HPLC, to afford the intermediate B03Z01-1(35 mg).

Step 2

[00369] The intermediate B03Z01-1 (35 mg, 1.0 eq.) was dissolved in 5 mL EtOAc, Pd/C (7 mg, 20%) was added and the mixture was stirred at rt. for 12 hours under H₂ balloon. The reaction was monitored by LCMS the stirring is continued until the double bond was reduced completely. The catalyst Pd/C was filtered off, and the solvent was removed under reduced pressure to afford the crude B03Z01 (20 mg) which was used as such for the next step.


Step 3

[00370] The intermediate B03Z01 (20 mg, 1.0 eq.) and 3,5-dimethylpiperidine (C01, 7.9 mg, 1.1 eq.) were dissolved in 2.5 mL of THF, the reaction mixture was stirred at 60 °C for 5 hours. The solvent was removed under reduced pressure to afford the crude product B03Z01C01. The crude product was then purified by prep-HPLC, to afford the target compound, 1-(3,5-dimethylpiperidin-1-yl)-3-(4,6-dimethoxy-2-hydroxy-phenyl)-3-(2-methoxypyrid-5-yl)propan-1-one (B03Z01C01, 11.8 mg), QC: 95.31%.

¹H NMR (400 MHz, CDCl₃) δ 8.53 (s, 1H), 8.02 (dd, J = 21.7, 8.6 Hz, 1H), 6.96 (dd, J = 8.9, 5.6 Hz, 1H), 6.32 (dd, J = 16.1, 2.2 Hz, 1H), 6.21 (d, J = 3.1 Hz, 1H), 5.99 (dd, J = 8.7, 2.0 Hz, 1H), 5.02 (d, J = 17.2 Hz, 1H), 3.97 (s, 3H), 3.79 (s, 3H), 3.75 (s, 3H), 3.45 – 3.34 (m, 2H), 3.03 (qd, J = 15.9, 4.4 Hz, 2H), 2.52 – 2.38 (m, 2H), 2.03 – 1.95 (m, 2H), 1.27 (s, 2H), 1.03 – 0.93 (m, 6H). MS (MeOH):[M+]⁺: 429.1, 362.1, 348.0, 316.3, 275.8, 186.1, 136.0.

Synthesis of salts of compounds of the invention

[00371] The representative salts of the compounds of the invention can be prepared following the general synthetic methods described below.



[00372] A round bottom flask is charged with the Compound 202 (0.001 mol) and THF (5 mL) and the mixture is stirred at room temperature. 0.5 mL of a sodium hydroxide solution (0.001 mol of NaOH) is added and the mixture was stirred for 30 minutes at room temperature. The solvents are removed at reduced pressure and the resultant semi-solid is taken up in diethyl ether where upon a white solid precipitated out upon standing. This mixture is allowed to sit at room temperature overnight. The solvent is decanted off and the solid dried under reduced pressure give the desired salt as a white solid.

[00373] Alternate Method for preparation of sodium salt: Compound 202 (44.1 mg, 0.10 mmol) and NaOH (0.10 mL of 1.0 N, 0.10 mmol) in 1.0 mL of water is stirred for 10 min. The clear solution is dried down by lyophilizer to give sodium salt of Compound 202 as a white powder.

[00374] The pharmaceutically acceptable salts of the compounds of formula I, wherein R³ is CO₂H, SO₃H, or CH₂CO₂H can be prepared following the procedures described above. For examples salts of Compound 99, 101, 201, 202, 317-332, 401-405, 407-412, 414, 416, 417, or 418 can be prepared using the procedures described above.

Assays

Development of a High-Throughput Screening Assay

[00375] Methods: The *Drosophila* S2 cell line was originally purchased from Invitrogen and was maintained in Schneider's medium supplemented with 10% heat-inactivated bovine fetal calf serum and antibiotics (Invitrogen). Gal4 DNA binding domain (G4DBD) corresponding to amino acids 1 through 147 of Gal4 protein was PCR amplified to make a fusion construct with mouse ROR γ t (amino acids 79 to the carboxyl terminal end) lacking its DNA binding domain. The resulting chimeric gene was subcloned into the copper inducible pMT/V5-His A vector (available from Invitrogen). In a similar manner, Gal4 fusion constructs were prepared with mouse ROR α (amino acids 142 to end) or *Drosophila* DHR3 (amino acids 120 to end). Coding sequences for firefly luciferase (available from Promega) were PCR amplified and subcloned into pUAST vector containing Gal4 binding enhancer sequences. pUAST is a commonly used *Drosophila* vector used by ordinarily skilled practitioners and has been described by Brand et al. (Development 118(2):401-415, 1993), the entire contents of which is incorporated herein in its entirety.

[00376] Renilla luciferase construct under the polIII promoter was obtained from Dr. Dasgupta's laboratory (NYU medical center). In order to generate stable cell lines, cells were co-transfected with pMT-G4DBD-ROR γ t, pMT-G4DBD-ROR α , pMT-G4DBD-DHR3, or pMT-G4DBDVP16 and pHygro plasmids (Invitrogen) and screened for resistant colonies in the presence of hygromycin (0.3 mg/mL). More than 150 independent ROR γ stable clones with luciferase reporters (pMt-ROR γ _luc) were tested for their suitability for the high-throughput screening (HTS) based on the following criteria: high signal-to background ratio in 384- and 1,536- well plates, their high induction rate upon the addition of copper, and ROR γ /t specificity probed by the dsROR γ - or ROR γ /t antagonist-mediated suppression. Positive clones were further transfected with pUAST-firefly luciferase, polIII-Renilla luciferase, and pCoPuro (Iwaki, Figuera et al. 2003) ("Rapid selection of *Drosophila* S2 cells with the puromycin resistance gene." *Biotechniques* **35**(3): 482-4, 486) and selected with puromycin (2.5 ug/ml). Seven clones were finally selected, and one of them (stable clone #25) was subsequently used for large-scale

HTS. Using similar methods, stable clones with genomic integration of the luciferase reporters and other reporters were generated such as pMT-ROR α _luc, pMT-DHR3_luc, or pMT-VP16_luc.

[00377] Results and Discussion: An activity-based assay system that permits high-throughput screening (HTS) for chemical modulators of ROR γ t transcriptional activity was developed. Since ROR γ t is located exclusively in cell nuclei, even when mutations are introduced in the putative ligand binding pocket, ROR γ t-dependent transcriptional activation, rather than the often used ligand-induced cytoplasm to nucleus translocation of hormone receptor, served as a better read-out. A cell-based assay was used to eliminate cell-impermeable or toxic molecules and to perform screening in a biologically relevant setting. The system employed provided a high signal-to-noise ratio and was able to handle a large-scale screen, as well as be cost-effective. S2 cells were derived from late stage *Drosophila melanogaster* embryos with hemocyte-like morphology and gene expression profiles (Schneider, I. *J Embryol Exp Morphol*, **1972**, 27, 353-65). They grew at room temperature as a semi-adherent monolayer with no requirement for CO₂, making it easy to apply large sets of small chemical molecules and to transfer cells without trypsin treatment.

[00378] Like other hormone receptors, ROR γ t contains both a DNA binding domain (DBD) and a ligand binding domain (LBD). The DBD was replaced with the heterologous yeast GAL4 DBD, because the endogenous DNA binding sites for ROR γ t are less well characterized.

[00379] The GAL4-ROR γ t fusion construct was placed under the control of a copper inducible promoter, and stable S2 cell lines with genomic integration of this construct were generated. The copper inducible promoter ensures a tight regulation of GAL4-ROR γ t expression and allows small molecules to get into the cells prior to its induction, thus increasing their effects on GAL4-ROR γ t. The reporter cells also carried the firefly luciferase reporter, whose expression is regulated by five copies of the GAL4 binding site enhancer (UAS) and a constitutive heat shock promoter, along with a control plasmid, pol III-driven Renilla luciferase. Pol III-Renilla luciferase was previously shown to serve as an excellent transfection and cell viability control in the S2 cell system. Use of Pol III-Renilla luciferase permitted normalization of ROR γ t-driven firefly luciferase activity and reduced cytotoxic effects and corrected for potential imprecise dispensation of cells in culture medium (Armknicht, S. et al. *Methods Enzymol*, **2005**, 392, 55-73). When Cu⁺⁺ was added, the ratio of firefly to Renilla luciferase activity (FR ratio) in these cells increased more than 100-fold compared to control cells lacking GAL4-ROR γ t (~34 fold increase compared to GAL4-ROR γ t cells treated with dsROR). ROR γ t induces robust transcriptional activation in *Drosophila* S2 cells in 384-well plates. For test with transient transfection, firefly reporter under GAL4 binding sites and Pol III-Renilla control plasmids were

transiently transfected along with dsRNA (75 ng), targeting EYFP or ROR γ , into both control or pMT-GAL4-ROR γ t stable S2 cell lines (10,000 cells/well). After three days, copper was added to induce GAL4-ROR γ t, and dual luciferase activity was measured following overnight incubation. The increase was also observed when the experiment was carried out in 384-well plates, demonstrating that it can be adopted as a high-throughput screen. Co-transfecting dsRNA that targets ROR γ t suppressed ROR-mediated firefly luciferase induction, demonstrating that this activity is ROR dependent.

[00380] In order to confirm that the ROR γ t function in S2 cells was physiologically relevant, it was first confirmed that *Drosophila* has a ROR γ t homologue. Mouse encodes three different ROR proteins, ROR α , ROR β , and ROR γ . ROR γ and ROR γ t are two isoforms that differ in non-translated N-terminal mRNA sequences. Indeed, *Drosophila* has one ROR homologue, *Drosophila* hormone receptor 3(DHR3) (King-Jones, K. & Thummel, C. S. *Nat Rev Genet*, **2005**, 6, 311-23). Structure-based alignment using BLAST revealed 48% amino acid identity between DHR3 and ROR γ t.

[00381] Next it was confirmed that ROR γ t ligands are likely present in *Drosophila* S2 cells. Since many ligands for nuclear hormone receptors are found to be sterols or their derivatives, growth of cells in medium lacking FBS (fetal bovine serum) or medium supplemented with fatty-acid stripped serum (charcoal treated) was attempted. Only a small decrease of the FR ratio was detected in cells grown in this condition, and the results were not conclusive. Previous studies have shown that the introduction of a single amino acid change inside the ligand binding pocket of ROR β abrogates its function as a transcriptional activator, suggesting that ROR β is a ligand-dependent hormone receptor. The crystal structure of the protein strongly suggested that replacement of alanine 269 with amino acids carrying bulkier side chains, such as valine and phenylalanine, would prevent binding of endogenous ligands without affecting the correct folding of the ligand binding domain (Stehlin, C. et al. *Embo J*, **2001**, 20, 5822-31). When the corresponding alanine residue in the putative ligand binding pocket of ROR γ t was replaced with phenylalanine, the mutant protein was no longer sufficient to induce Th17 cell differentiation when transduced into naive mouse CD4⁺ T cells, consistent with the presence of cognate ROR γ t ligand(s) in these cells. The Ala to Phe mutation in ROR γ t also completely abrogated transcriptional activation of firefly luciferase expression without affecting the transcription of control Renilla luciferase, suggesting that ROR γ t ligand is present in the *Drosophila* assay system. Indeed, introduction of alanine to phenylalanine (F) mutation in a putative ligand binding pocket abolishes activity of ROR γ t in this system. As confirmed by immunoblot, the alanine to phenylalanine mutation did not, however, affect protein stability.

[00382] DHR3 is transcriptionally regulated by 20-hydroxyecdysone (20E) and is essential for fly larval development (King-Jones, *supra*). It has been shown that E75, another 20E-dependent fly nuclear hormone receptor, negatively regulates the function of DHR3 (White, K. P., Hurban, P., Watanabe, T. & Hogness, D. S. *Science*, **1997**, 276, 114-17; Reinking, J. et al. *Cell*, **2005**, 122, 195-207. Indeed, co-expression of E75a or E75b (two *Drosophila* E75 isoforms) decreased the level of DHR3-mediated transcriptional activation in a dosage-dependent manner. E75 is a hormone receptor having antagonizing activities of DHR3 and ROR γ t. Transfection of increased amount of E75a or E75b resulted in concomitant reduction of FR ratio. Each well received the same amount of DNA in transfection mix. These fly genes also function as dosage-dependent negative regulators for mouse ROR γ t activity in S2 cells, without affecting the functions of an irrelevant transcriptional activator VP16, strongly suggesting that the ROR/DHR3 core regulatory mechanism is conserved between mouse and fly systems. Collectively, these data confirm the accuracy and relevance of the above approach utilizing the heterologous S2 cell system in order to identify chemical agonists or antagonists of the mouse hormone receptor ROR γ t.

Measurement of Luciferase activity.

[00383] Methods: Promega Dual-Glo system is widely used for HTS as the luciferase substrates. Cell culture medium was reduced to the final volume of 10 μ l or less and 10 μ l of Dual-glo and 10 μ l of Stop-glo luciferase substrates were added in a sequential manner (Promega). Firefly and Renilla luciferase activity was determined by measuring luminescence signals using an automated 384-well plate reader equipped with multiple stack units (such as the Analyst GT or Envision plate readers).

[00384] Results and Discussion: The Dual-Glo luciferase assay system from Promega facilitated measuring luciferase activity in HTS. First, it did not require a washing step, and the luciferase activities of both the firefly and the Renilla could be measured in the same well one after the other. Second, the signals that it produced remained stable for more than two hours, making it possible to measure activity from many different plates for a given experiment. Since the reagents are expensive, the volume of medium was reduced to one third prior to adding luciferase substrates, so that fewer substrates were used. However, when minimizing cost is less of a priority, the luciferase substrates used in the primary assay may be directly added to cells without going through this additional step.

HTS for identification of ROR γ t antagonists using ROR γ t-luc stable cell lines

[00385] Methods: 600 G4DBD-ROR γ t-luc reporter (#25) or G4DBD-VP16-luc reporter cells were distributed into each well of 1,536-well white bottom plates in 4 μ l S2 cell culture

volume containing hygromycin (300 µg/ml) and puromycin (2 µg/ml). Small compounds in seven different concentrations range from 46 µM to 1.7 nM were pin-transferred (23 nl) by a robot (Inglese et al., 2006, Proc. Natl. Acad. Sci. 103:11473-8). After one-hour incubation, 1 µl of culture medium solution containing copper sulfate (to final 0.7 mM) and 10 µM RORγ/γt antagonists were added to each well. After 20-hour incubation at ambient temperature, 1.5 µl firefly luciferase detection mix was added and the luciferase activities were measured in 10 min. ViewLux luminometers were used for measuring luciferase signal.

[00386] Results and Discussion: Even though G4BD-RORγt stable cells with transient transfection of two luciferase constructs were successfully used for small-scale screening and led the present inventors to identify specific RORγ/γt antagonists in Harvard LCCB, it became problematic to apply the same method to larger scale screens with chemical libraries covering more than 250,000 compounds. First, transient transfection method often produced well-to-well variation due to incomplete mixing and unequal distribution of transfection mix. There is also day-to-day variation when preparing the master transfection mix. Second, in order to save reagent and to handle large quantities of chemicals, it was necessary to do the screen with reduced numbers of cells in a smaller culture volume. Moreover, performing the screen with 1,536-well plates is more efficient than performing the screen with 384-well plates. Thus, new RORγ/γt-luc reporter stable cells were developed to eliminate the necessity of repeated transfection and to achieve increased well-to-well consistency. When tested in a 384-well plate, even small numbers of cells (400 cells/well) gave high firefly luciferase signal (thus high RORγ/γt activity), which is suppressed (22-fold reduction when 400 cells are used) by addition of a RORγ/γt antagonist. The new stable cell line systems also turned out to be suitable for HTS in 1,536-well plates, because z' value is 0.75 when 600 cells are used per well with 10 µl total cell culture volume.

[00387] Using RORγ/γt-luc reporter lines, the pilot screen with the LOPAC (Sigma) library was performed through a NIH roadmap program to identify RORγ/γt antagonist compounds. LOPAC contains 1,280 pharmacologically active compounds. Among these, approximately 40 compounds were found as initial hits (~0.3%). These hits were tested against validation screens to identify RORγ/γt specific compounds. To facilitate a large-scale validation, VP16-luc reporter cell lines with genomic integrations of G4BD-VP16, UAS-ffluc, and polIII-Rluc were developed as discussed earlier. These cells also exhibited robust and consistent VP16 activity in 1,536-well plates (data not shown), and thus can be used as a good control reporter to weed-out compounds inhibiting general transcription, the function of GAL4 DNA binding domain, and a nuclear import of GAL4 chimeric proteins. Indeed, many compounds were

identified as initial hits to reduce ROR γ / γ t activity from the pilot LOPAC screen, but later were found to be non-specific inhibitors, because they reduced both ROR γ / γ t and VP16 activities. Intriguingly, previously identified ROR γ / γ t specific antagonists identified by small scale HTS, also selectively inhibited ROR γ / γ t activity without affecting VP16, confirming their specificity on ROR γ / γ t. A large-scale screen covering more than 250,000 compounds was carried out against ROR γ / γ t-luc and VP16-luc reporter systems in parallel to identify ROR γ / γ t specific antagonists in a systematic manner.

[00388] Secondary assays directed toward evaluating the ability of such compounds to suppress mouse or human Th17 cell differentiation are also encompassed herein. Exemplary secondary assays that serve to confirm *bona fide* ROR γ inhibitors include without limitation:

Secondary screening lists

- 1) S2 cell reporter system: Identified hits from HTS are further screened and their specificity confirmed by testing against ROR γ -luc, VP16-luc, ROR α -luc, and DHR3-luc reporter S2 cell lines. Compounds either having no activity on VP16, ROR α , and DHR3 or having ten times higher IC₅₀ values on such reporters are selected for further tests.
- 2) Cytokine induced mouse Th17 cells differentiation. Effects on mouse endogenous ROR γ t in a relevant physiological setting were determined by testing compounds in the Th17 cell differentiation assay. Compounds having ROR γ t inhibitory activity are predicted to suppress Th17 cell differentiation. Th1 or regulatory T cell differentiation was used as a counter-screen method to select specific compounds that only affect Th17 cell differentiation without having pleiotrophic effects on general T cell proliferation or cytokine production.
- 3) ROR dependent Th17 cell differentiation. Compounds were further tested, by examining their effects on T cells expressing ROR α or ROR γ . Compounds that directly inhibit ROR γ are expected to inhibit ROR γ - but not ROR α - dependent Th17 cell differentiation. Compounds affecting IL17a production or ROR regulatory pathways, however, are expected to inhibit both.
- 4) Human Th17 cell differentiation. Compound effects on human ROR γ t will be tested by treating human cord blood CD4 T cells with select compounds to determine if such compounds alter differentiation into Th17 lineages.

[00389] With aspects of the claimed invention now being generally described, these will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain features and embodiments of the presently claimed invention and are not intended to be limiting.

EXAMPLES

[00390] As detailed above, in order to identify small molecules to antagonize ROR γ / γ t transcriptional activity, the present inventors developed insect cell line based reporter systems, expressing murine ROR γ / γ t or closely related transcriptional activators. Since their cognate DNA binding sites were not well characterized, the DNA binding domains (DBD) of ROR γ / γ t, ROR α (mouse homolog for POP γ), and DHR3 (*Drosophila* orthologue for ROR family proteins) were replaced with the heterologous yeast GAL4 DBD. The transcriptionally active domain of general transcriptional activator VP16 was also fused with GAL4 DBD. The GAL4 fusion constructs were placed under the control of a copper inducible promoter, and stable S2 cell lines with genomic integration of these four reporter constructs were generated. The copper inducible promoter ensures tight regulation of GAL4-fusion protein expression and it allows small molecules to get into the cells prior to protein induction, thus increasing their effects on GAL4 reporters. The stable reporter cell lines also encode the firefly luciferase reporter, whose expression is regulated by five copies of the GAL4 binding site enhancer (UAS), along with the pol III-driven Renilla luciferase reporter. Pol III-Renilla luciferase was included to serve as cell viability control in the S2 cell system (Armknrecht, S. *et al. Methods Enzymol* **392**, 55-73 (2005).

[00391] From screening a chemical compounds library consisting of 4,812 compounds, including known Bioactives and Prestwick collections, a number of compounds were identified as small molecule inhibitors for the ROR γ / γ t transcriptional activity.

IC₅₀ Determinations




[00392] A cell-based reporter assay was used to detect ROR γ t-mediated activity. This assay, called ROR γ t employed *Drosophila* Schneider cells that were stably transfected with two vectors: a gene expressing a fusion of the Gal4 DNA binding domain and ROR γ t transactivation domain under the control of the metallothionine promoter and a *Photinus* luciferase reporter regulated by the Gal4 binding site enhancer, UAS. Copper addition to the medium induced expression of the Gal4-ROR γ t fusion, which subsequently induced expression of the UAS-luciferase reporter. Small molecule inhibitors of ROR γ t activity were detected by a decrease in luciferase reporter activity. Cells (600/well) were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23 nL compound or DMSO vehicle by a pin tool, the plates were incubated 1 hr at ambient temperature, and 1 uL/well copper sulfate (700 uM final concentration) was added. The plates were centrifuged 15 s at 1000 RPM and incubated 20 hr at ambient temperature. After addition of 1.5 uL *Photinus* luciferase







detection reagent, the plates were incubated 10 min at ambient temperature and then read by a ViewLux (Perkin Elmer) to detect luminescence. The concentration-response data were fit using a reported algorithm (Wang, Y. et al. Current Chemical Genomics, 2010, 57-66). Efficacy is expressed as % of the maximal response of control inhibitor (Digoxin), set at 100%. IC₅₀ is the concentration at which compound exhibits half-maximal efficacy.








[00393] A number of representative amido compounds of this invention were or can be tested for their inhibitory activity. The amido compounds of the invention along with their IC₅₀ and Efficacy values, as determined using conventional methods to those skilled in the art, are listed below in Table 1. For the purpose of Table 1 and Table 1A, the IC₅₀ values are expressed as follows:

- ++++ compound exhibited IC₅₀ < 1 μ M
- +++ compound exhibited IC₅₀ 1-10 μ M
- ++ compound exhibited IC₅₀ 11-50 μ M
- + compound exhibited IC₅₀ >50 μ M

[00394] TABLE 1: IC₅₀ Values for Exemplary Compounds

Sample ID	Compd #	Structure	MW (Calcd)	MW (obsvd)	IC ₅₀ (μ M)	Efficacy (%)
NCGC00238411	70		389.52	390.30	+++	-95.0
NCGC00242603	79		453.61	454.20	+++	90.8
NCGC00242608	83		475.61	476.20	+++	-93.79






Sample ID	Compd #	Structure	MW (Calcd)	MW (obsvd)	IC ₅₀ (μM)	Efficacy (%)
NCGC00242609	84		504.65	505.20	++	-102.71
NCGC00242620	95		480.61	481.20	+++	-93.06
NCGC00242624	99		441.53	442.20	+++	-92.59
NCGC00242625	100		439.56	440.20	++++	-93.60
NCGC00242626	101		441.53	442.20	+++	-88.72
NCGC00242632	106		398.51	399.20	+++	-96.9

Sample ID	Compd #	Structure	MW (Calcd)	MW (obsvd)	IC ₅₀ (μM)	Efficacy (%)
NCGC00242633	107		403.54	404.20	+++	-94.9
NCGC00242634	108		398.51	399.20	++	-118.67
NCGC00242606	111		440.54	441.20	+++	-96.74
NCGC00242631	139		451.52	452.20	+++	-94.5
NCGC00242638	142		368.48	369.10	+	-9.3
NCGC00242642	146		432.52	433.10	+++	-94.07
NCGC00249676	201		455.5	456.1	++++	-87






* The stereochemistry is not confirmed.






[00395] The following additional representative amido compounds of this invention, which are prepared in according the methods described herein or can be prepared following the methods described in the literature or following the methods known to those skilled in the art, are given in Table 1A, Table 1B, and Table 1C.






[00396] **TABLE 1A: Additional Compounds of the Invention**






Sample ID	Compd #	Structure	MW (Calcd)	MW (obsvd)	IC ₅₀ (μM)
NCGC0024 9675	202		441.53	442.20	++++
A03Y01C01	203		403.53	402.1	+++
A04Y01C01	204		401.51	400.1	+++
A05Y01C01	205		456.61	455.1	++++
B03Z01C01	206		431.56	429.1	++++






[00397] TABLE 1B: Further Additional Compounds of the Invention






Compd #	Structure	MW (Calcd)
301		387.48
302		448.57
303		448.57
304		415.54
305		387.48







Compd #	Structure	MW (Calcd)
306		404.53
307		400.52
308		383.49
309		396.54
310		409.58







Compd #	Structure	MW (Calcd)
311		369.47
312		443.49
313		375.49
314		377.46
315		391.49





Compd #	Structure	MW (Calcd)
316		405.52
317		412.49
318		426.52
319		440.54
320		480.49





Compd #	Structure	MW (Calcd)
321		414.46
322		428.52
323		442.54
324		482.49
325		412.49

Compd #	Structure	MW (Calcd)
326		426.52
327		440.54
328		480.49
329		414.46
330		428.52


Compd #	Structure	MW (Calcd)
331		442.54
332		482.49
333		453.54
334		453.54
335		424.50
336		438.53


Compd #	Structure	MW (Calcd)
337		452.56
338		492.50
339		426.50
340		440.53
341		454.56
342		494.50

Compd #	Structure	MW (Calcd)
343		424.50
344		438.53
345		452.56
346		492.50

Compd #	Structure	MW (Calcd)
347		426.50
348		440.53
349		454.56
350		494.50







[00398] TABLE 1C: More Additional Compounds of the Invention

Compd #	Structure	MW (Calcd)
401		475.97

Compd #	Structure	MW (Calcd)
402		475.97

Compd #	Structure	MW (Calcd)
403		455.56
404		465.56
405		443.50
406		518.63
407		475.97

Compd #	Structure	MW (Calcd)
408		431.47
409		456.54
410		475.97
411		475.97
412		455.56

Compd #	Structure	MW (Calcd)	Compd #	Structure	MW (Calcd)
413		465.56	416		475.97
414		443.50	417		449.46
415		518.63	418		456.54

Th17 Assay

Effects of compound derivatives at various concentrations on mouse Th17 polarization

[00399] Percentage of DMSO treated IL-17a producing cells was set at 100. Naive mouse CD4 T cells (CD25⁻, CD62L⁺, and CD44^{low-int}) were sorted and cultured with CD3/CD28 stimulatory antibodies in the presence of TGFβ (0.1ng/ml) and IL6 (20ng/ml). Compounds were added on Day 1 and cells were analyzed on Day 4. For intracellular cytokine staining, cells were incubated for 5 h with phorbol ester (50 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma) and GolgiStop (BD). When needed, surfaces were stained by incubation for 15 min on ice with PECy7-conjugated CD4 (BD Biosciences). The Cytofix/Cytoperm buffer set (BD) was used for intracellular staining. Cells were fixed and made permeable for 30 min on ice and were stained for 30 min on ice in permeabilization buffer with Alexa647-conjugated anti-IL17a (eBioscience) and PE-conjugated anti-IFNγ (eBioscience). An LSR II (BD Biosciences) and FlowJo software

(Tree Star) were used for flow cytometry. ROR γ IC₅₀ value acquired from the S2 cell reporter assay is listed for comparison.


[00400] A number of representative amido compounds of this invention were or can be tested for their Th17 inhibitory activity. The exemplary amido compounds of the invention along with their Th17 and S2 ROR γ IC₅₀ values, as determined using conventional methods to those skilled in the art, are listed below in Table 2. For the purpose of Table 2, the IC₅₀ values are expressed as follows:

++++ compound exhibited TH17 IC₅₀ < 1 μ M
 +++ compound exhibited TH17 IC₅₀ 1-10 μ M
 ++ compound exhibited TH17 IC₅₀ 11-20 μ M
 + compound exhibited TH17 IC₅₀ >20 μ M
 **** compound exhibited ROR γ IC₅₀ < 1 μ M
 *** compound exhibited ROR γ IC₅₀ 1-10 μ M
 ** compound exhibited ROR γ IC₅₀ 11-20 μ M
 * compound exhibited ROR γ IC₅₀ >20 μ M

[00401] Table 2: Th17 and ROR γ S2 Cell IC₅₀ values for Exemplary Compounds

ID	Compd ID	Th 17 IC ₅₀ μ M	S2 cell ROR γ IC ₅₀ μ M
NCGC00238427	RC1	+++	****
NCGC00242624	99	+++	****
NCGC00242626	101	+	***

[00402] Figure 1 shows FACS plot analyses demonstrating that NCGC00242624 (ID 99) and NCGC00238427 (at the indicated concentrations) suppress mouse Th17 cell differentiation, as measured by IL17a production. As shown in Figure 2, NCGC00242624 suppresses human Th17 cell differentiation to a degree similar to that of NCGC00238427 (RC1).



RC1 (NCGC00238427)

[00403] With respect to the methodological details pertaining to Figure 1, naive CD4 T cells (CD25⁻, CD62L⁺, and CD44^{low-int}) were sorted and cultured with CD3/CD28 stimulatory antibodies in the presence of TGFβ (0.1ng/ml) and IL6 (20ng/ml). Compounds were added on Day 1 and cells were analyzed on Day 4. For intracellular cytokine staining, cells were incubated for 5 h with phorbol ester (50 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma) and GolgiStop (BD). The Cytotfix/Cytoperm buffer set (BD) was used for intracellular staining. Cells were fixed and made permeable for 30 min on ice and were stained for 30 min on ice in permeabilization buffer with Alexa647-conjugated anti-IL17a (eBioscience) and PE-conjugated anti-IFNγ (eBioscience). An LSR II (BD Biosciences) and FlowJo software (Tree Star) were used for flow cytometry.

[00404] Figure 2 shows FACS plot analyses demonstrating that treatment with either 0.5 μM NCGC00242624 (ID 99) or NCGC00238427 selectively suppresses human Th17 cell differentiation. Figure 2 also reveals that treatment with either 0.5 μM NCGC00242624 or NCGC00238427 does not inhibit Th1 cell differentiation, as measured by IFNγ production, from naive CD4 T cells. These results suggest that NCGC00242624 and NCGC00238427 do not inhibit general T cell proliferation or cytokine production. For Th1 differentiation, IL12 (10 ng/ml) and IL2 (100 U/ml) were added to naive CD4 T cell cultures instead of TGFβ and IL6.

[00405] Figure 3 shows FACS plot analyses revealing that treatment with either 0.5 μM NCGC00242624 or NCGC00238427 selectively inhibits RORγt overexpression dependent IL17a production in human CD4 T cells. RORα overexpression dependent IL17a production in human CD4 T cells is, however, unaffected by treatment with either 0.5 μM NCGC00242624 or NCGC00238427. These results demonstrate that the effect of these compounds is selective for RORγt dependent human Th17 cell differentiation. Briefly, CD3⁺ CD4⁺ CD45RA⁺ naive human T cells were isolated from peripheral blood derived from healthy donors. The naive T cells were cultured in XViVO-20 (Lonza) medium for 7 days in the presence of IL2 and stimulatory CD3 and CD28 antibodies. Cells were infected with lentivirus encoding human RORα or RORγ and compound or DMSO was added on day 2. FACS plot analysis is shown after gating on GFP expressing (virus infected) cells.

Half-life in human liver microsomes (HLM)

[00406] Test compounds (1 μM) are incubated with 3.3 mM MgCl₂ and 0.78 mg/mL HLM (HL101) in 100 mM potassium phosphate buffer (pH 7.4) at 37°C on the 96-deep well plate. The reaction mixture is split into two groups, a non-P450 and a P450 group. NADPH is only added to the reaction mixture of the P450 group. An aliquot of samples of the P450 group is collected at 0, 10, 30, and 60 min





time points, where the 0 min time point indicated the time at which NADPH is added into the reaction mixture of the P450 group. An aliquot of samples of non-P450 group is collected at -10 and 65 min time points. Collected aliquots are extracted with acetonitrile solution containing an internal standard. The precipitated protein is spun down in centrifuge (2000 rpm, 15 min). The compound concentration in supernatant is measured by LC/MS/MS system.


[00407] The half-life value is obtained by plotting the natural logarithm of the peak area ratio of compounds/ internal standard versus time. The slope of the line of best fit through the points yields the rate of metabolism (k). This is converted to a half-life value using following equations:

$$\text{Half-life} = \ln 2 / k$$

[00408] The results of the tests and corresponding $t_{1/2}$ values are set forth in Table 3, below.

[00409] **TABLE 3: Half Life ($t_{1/2}$) of Exemplary Compounds**

Sample ID	Compd #	Structure	% Remaining @ 60 min	CL _{int} (uM/min/mg proteins)	$t_{1/2}$ (min)
Verapamil			16.49	62.8	22.1
NCGC00242624	99		51.36	21.6	64.2
NCGC00242637	141		9.02	107.8	12.9
NCGC00242649	150		6.79	173.2	8

Sample ID	Compd #	Structure	% Remaining @ 60 min	CL _{int} (uM/min/mg proteins)	t _{1/2} (min)
NCGC00242657	157		6.78	200.8	6.9

[00410] The above stability data shows that the compounds of the present invention, ID 99 and 141, have better or improved stability over the compounds with IDs 150 and 157. The compound 99 also showed improved stability with respect to verapamil.


[00411] From the foregoing description, various modifications and changes in the compositions and methods of this invention will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein.

[00412] All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

[00413] The chemical names of compounds of invention given in this application are generated using Open Eye Software's Lexichem naming tool, Symyx Renaissance Software's Reaction Planner or MDL's ISIS Draw Autonom Software tool and not verified. Preferably, in the event of inconsistency, the depicted structure governs.

WHAT IS CLAIMED IS:

1. A method for preventing, treating or ameliorating in a mammal a disease or condition that is causally related to ROR γ t activity in vivo, which comprises administering to the mammal an effective disease-treating or condition-treating amount of a compound according to formula I:



or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;

wherein

each Cy¹ and Cy² is independently selected from substituted or unsubstituted aryl and heteroaryl;

each n₁ and n₂ is independently 1, 2, 3, 4 or 5;

each R^{1a} and R^{1b} is independently H, substituted or unsubstituted C₁-C₆ alkyl, or CN; or

R^{1a} and R^{1b} joined together to form cycloalkyl ring;

R² is H, substituted or unsubstituted C₁-C₆ alkyl, or aryl;

or one of R^{1a} and R^{1b} is joined to the C of CR² to form a cyclopropyl ring; or R² is joined to the C of CR^{1a}R^{1b} to form a cyclopropyl ring;


each R³ and R⁴ is independently selected from H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or

unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thiol; or any two adjacent R^3 groups, or any two adjacent R^4 groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring; each R^5 and R^6 is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroarylalkyl; or

R^5 and R^6 , together with the N they are attached to, form a 4-12 membered substituted or unsubstituted heterocycloalkyl;

provided that

- i) at least one of Cy^1 and Cy^2 is heteroaryl; and
- ii) when the compound is



;


then the compound is in the form of an acid addition salt;

or

provided that

i) when each of Cy^1 and Cy^2 is phenyl; then at least one R^3 is selected from CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; and wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring;

- ii) when the compound is




then the compound is in the form of a sodium, potassium, calcium, or ammonium salt; and

iii) the compound is other than the compounds listed in Table 1, wherein compound ID is 83, 84, 95, 100, 111, or 139.

2. The method according to claim 1, wherein each R^5 and R^6 is independently selected from H, substituted or unsubstituted alkyl, substituted and unsubstituted cycloalkyl, and substituted and unsubstituted phenyl.
3. The method according to claim 1, wherein one of R^5 and R^6 is H or Me; and the other is independently selected from H, substituted or unsubstituted alkyl, substituted and unsubstituted cycloalkyl, and substituted and unsubstituted phenyl.
4. The method according to claim 1, wherein each R^5 and R^6 is independently selected from substituted or unsubstituted alkyl.
5. The method according to claim 1, wherein each R^5 and R^6 is independently selected from unsubstituted alkyl.
6. The method according to claim 1, wherein each R^5 and R^6 is independently selected from H, Me, Et, n-Pr, i-Pr, n-Bu, and t-Bu.
7. The method according to claim 1, wherein each R^5 and R^6 is independently selected from H, and alkyl substituted with hydroxyl, amino, alkylamino, dialkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.
8. The method according to claim 1, wherein each R^5 and R^6 is independently selected from H, Me, Et, hydroxyethyl, hydroxypropyl, aminoethyl, aminopropyl, dimethylaminoethyl, dimethylaminopropyl, piperidinoethyl, morpholinoethyl, cyclopropylmethyl, benzyl, phenethyl, and furanylmethyl.
9. The method according to claim 1, wherein each R^5 and R^6 is independently selected from H, and cycloalkyl.
10. The method according to claim 1, wherein each R^5 and R^6 is independently selected from H, and cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
11. The method according to claim 1, wherein R^5 is H; and R^6 is selected from hydroxyethyl, hydroxypropyl, aminoethyl, aminopropyl, dimethylaminoethyl, dimethylaminopropyl, piperidinoethyl, morpholinoethyl, cyclopropylmethyl, cyclohexyl, benzyl, phenethyl, and furanylmethyl.
12. The method according to claim 1, wherein R^5 and R^6 are joined together to form a 4-12 membered substituted or unsubstituted heterocycloalkyl.
13. The method according to Claim 13, wherein R^5 and R^6 are joined together to form azetidiny, pyrrolidiny, piperidiny, piperiziny, morpholiny, tetrahydroquinoliny,

indoliny, or azepiny, unsubstituted or substituted with one or more alkyl, substituted alkyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, alkoxy, hydroxyl, CN, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, amido, acyl, aroyl, or -CO-alkoxy.

14. The method according to Claim 1, wherein the compound is according to formula IIa, IIb, IIc, IIe, or IIf:




or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;


and wherein Cy1, Cy2, n1, n2, R^{1a}, R^{1b}, R², R³, R⁴, R⁵, and R⁶ are as in claim 1; and each R^{5a} and R^{5b} is independently H, alkyl, substituted alkyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, alkoxy, hydroxyl, CN, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, amido, acyl, aroyl, or -CO-alkoxy.

15. The method according to any one of claims 1-14, wherein each of Cy¹ and Cy² is phenyl.
16. The method according to any one of claims 1-14, wherein one of Cy¹ and Cy² is heteroaryl; and the other is phenyl.
17. The method according to any one of claims 1-14, wherein each of Cy¹ and Cy² is heteroaryl.
18. The method according to any one of claims 1-17, wherein n2 is 1, 2, or 3.
19. The method according to any one of claims 1-17, wherein n2 is 1, 2, or 3; and each R⁴ is independently selected from halo, C₁-C₆ alkyl, CN, OH, and C₁-C₆ alkoxy.

20. The method according to any one of claims 1-17, wherein n_2 is 1, 2, or 3; and each R^4 is independently selected from Cl, Me, OH, and C_1 - C_6 alkoxy.
21. The method according to Claim 1, wherein the compound is according to formula IIIa, IIIb, or IIIc:




IIIa



IIIb

or



IIIc

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;

wherein

n_1 , R^{1a} , R^{1b} , R^2 , R^3 , and R^4 , are as in claim 1; n_2 is 1, 2, or 3;

each HET^1 and HET^2 is independently selected from heteroaryl;

$R^{3'}$ is R^3 ; $R^{4'}$ is R^4 ; $n'1$ is n_1 ; $n'2$ is n_2 ;

A is $CR^{8a}R^{8b}$, NR^{8a} , O, or S; m is 0 or 1;

each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; and t is 0, 1, 2, or 3;

R^{7a} is H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkythio, substituted or unsubstituted alkoxy carbonyl, substituted or unsubstituted alkylaryl amino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted

arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thio;


R^{7b} is R^4 ; or any two adjacent R^4 and R^{7b} groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring; and

each R^{8a} and R^{8b} is independently H, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

provided that

i) when the compound is according to formula IIIa, then at least one R^3 is selected from CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; and wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring;


ii) when the compound is




then the compound is in the form of a sodium, potassium, calcium, or ammonium salt; and

iii) the compound is other than the compounds listed in Table 1, wherein compound ID is 83, 84, 95, 100, 111, and 139.

22. A compound according to formula IIIa, IIIb, or IIIc:




IIIa



IIIb

or



IIIc

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;

wherein

n_1 , R^{1a} , R^{1b} , R^2 , R^3 , and R^4 , are as described for formula I; n_2 is 1, 2, or 3;

each HET^1 and HET^2 is independently selected from heteroaryl;

$R^{3'}$ is R^3 ; $R^{4'}$ is R^4 ; n_1 is n_1 ; n_2 is n_2 ;

A is $CR^{8a}R^{8b}$, NR^{8a} , O, or S; m is 0 or 1;

each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; and t is 0, 1, 2, or 3;

R^{7a} is H, OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thio;

R^{7b} is R^4 ; or any two adjacent R^4 and R^{7b} groups may join together to form a substituted or unsubstituted carbocyclic or heterocyclic ring; and


each R^{8a} and R^{8b} is independently H, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

provided that

i) when the compound is according to formula IIIa, then at least one R^3 is selected from CO_2H , CH_2CO_2H , COR^{3a} , $CONR^{3a}R^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; and wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring;

ii) when the compound is according to formula IIIa, R^3 is $CONR^{3a}R^{3b}$, R^{3a} and R^{3b} joined together to form a morpholino ring, m is 1, and A is O; then R^{7a} is other than H;

iii) when the compound is



then the compound is in the form of a sodium, potassium, calcium, or ammonium salt;

iv) the compound is other than the compounds listed in Table 1, wherein compound ID is 83, 84, 95, 100, 111, and 139;

v) when the compound is according to formula IIIb; then R^{7a} is other than H;

vi) when the compound is according to formula IIIb, HET^1 is furanyl or quinolin-3-yl, and each of $R^{3'}$ and R^4 is H; then R^{7a} is other than H or methoxy;

vii) when the compound is according to formula IIIb, and HET^1 is pyrrolyl; then R^{7a} is other than H or methyl; and


viii) when the compound is according to formula IIIb; then HET^1 is other than benzopyranyl;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.

23. The method or compound according to any one of Claims 21-22, wherein each of R^{7a} and R^{7b} is independently OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkylarylamino, substituted or unsubstituted amino, substituted or unsubstituted arylalkyl, sulfo, substituted sulfo, substituted sulfonyl, substituted sulfinyl, substituted sulfanyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted arylsulfonyl, azido, substituted or unsubstituted carbamoyl, carboxyl, cyano, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted dialkylamino, halo, nitro, and thio.
24. The method or compound according to any one of Claims 21-22, wherein each of R^{7a} and R^{7b} is independently OH, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, CN, halo, amido, or haloalkyl.
25. The method or compound according to any one of Claims 21-22, wherein each of R^{7a} and R^{7b} is independently halo, C₁-C₆ alkyl, CN, OH, or C₁-C₆ alkoxy.
26. The method or compound according to any one of Claims 21-22, wherein each of R^{7a} and R^{7b} is independently Cl, F, Me, CF₃, CN, OH, or OMe.
27. The method or compound according to any one of Claims 21-22, wherein one of R^{7a} and R^{7b} is OH; and the other is alkoxy.
28. The method or compound according to any one of Claims 21-22, wherein each of R^{7a} and R^{7b} is OH or alkoxy.
29. The method or compound according to any one of Claims 21-22, wherein one of R^{7a} and R^{7b} is OH; and the other is OMe.
30. The method or compound according to any one of Claims 1-29, wherein R^{1a} and R^{1b} is independently H, CN, or Me.
31. The method or compound according to any one of Claims 1-29, wherein each of R^{1a} and R^{1b} is H or Me.
32. The method or compound according to any one of Claims 1-29, wherein one of R^{1a} and R^{1b} is H; and the other is CN.
33. The method or compound according to any one of Claims 1-32, wherein m is 0.
34. The method or compound according to any one of Claims 1-32, wherein m is 1; and A is C or N.

35. The method or compound according to any one of Claims 21-34, wherein HET¹ is selected from pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, triazolyl, oxadiazolyl, and thiadiazolyl.
36. The method or compound according to any one of Claims 21-34, wherein HET¹ is selected from pyridyl, pyrimidyl, and pyrazinyl.
37. The method or compound according to any one of Claims 21-34, wherein HET¹ is selected from indolyl, benzimidazolyl, 2-oxobenzimidazolyl, benzofuranyl, benzothiazolyl, and benzthiophenyl.
38. The method or compound according to any one of Claims 21-34, wherein HET² is selected from pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, triazolyl, oxadiazolyl, and thiadiazolyl.
39. The method or compound according to any one of Claims 21-34, wherein HET² is selected from pyridyl, pyrimidyl, and pyrazinyl.
40. The method or compound according to any one of Claims 21-34, wherein HET² is selected from indolyl, benzimidazolyl, 2-oxobenzimidazolyl, benzofuranyl, benzothiazolyl, and benzthiophenyl.
41. The method or compound according to any one of Claims 1-40, wherein R⁴ is H, alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, alkoxyalkyl, amido, hydroxyl, cyano, or alkoxy.
42. The method or compound according to any one of Claims 1-40, wherein R⁴ is H, halo, C₁-C₆ alkyl, CN, OH, or C₁-C₆ alkoxy.
43. The method or compound according to any one of Claims 1-40, wherein R⁴ is H, Cl, F, Me, CF₃, CN, OH, or OMe.
44. The method or compound according to any one of Claims 1-43, wherein n₁ is 1, 2 or 3.
45. The method or compound according to any one of Claims 1-43, wherein n₁ is 1.
46. The method or compound according to either of Claims 1 or 22, wherein the compound is according to formula IVa, IVb, IVc, IVd, IVe, or IVf:



or a pharmaceutically acceptable salt, solvate or prodrug thereof;


or stereoisomers, isotopic variants and tautomers thereof;

and wherein R^2 , R^5 , and R^6 are as in claim 1;

R^3 is selected from CO_2H , $\text{CH}_2\text{CO}_2\text{H}$, COR^{3a} , $\text{CONR}^{3a}\text{R}^{3b}$, SO_3H , SOR^{3a} , SO_2R^{3a} , and heteroaryl; wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; or R^{3a} and R^{3b} may join together to form a substituted or unsubstituted heterocyclic ring;


each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; t is 0, 1, 2, or 3; provided that

i) when the compound is




then the compound is in the form of a sodium, potassium, calcium, or ammonium salt; and

ii) the compound is other than



47. The method or compound according to any one of Claims 1-46, wherein R^3 is CO_2H .
48. The method or compound according to any one of Claims 1-46, wherein R^3 is SO_3H .
49. The method or compound according to any one of Claims 1-46, wherein R^3 is CH_2CO_2H .
50. The method or compound according to any one of Claims 1-46, wherein R^3 is heteroaryl.
51. The method or compound according to any one of Claims 1-46, wherein R^3 is pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, triazolyl, oxadiazolyl, thiadiazolyl, and tetrazolyl.
52. The method or compound according to any one of Claims 1-46, wherein R^3 is 1,3,4-triazolyl or tetrazol-5-yl.
53. The method or compound according to any one of Claims 1-46, wherein R^3 is $CONR^{3a}R^{3b}$; wherein each R^{3a} and R^{3b} is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
54. The method or compound according to any one of Claims 1-53, wherein R^{3b} is H.
55. The method or compound according to any one of Claims 1-53, wherein R^{3b} is alkyl.
56. The method or compound according to any one of Claims 1-53, wherein R^{3b} is Me, Et, or i-Pr.
57. The method or compound according to any one of Claims 1-46, wherein R^3 is selected from COR^{3a} , SOR^{3a} , and SO_2R^{3a} ; wherein R^{3a} is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

58. The method or compound according to any one of Claims 1-57, wherein R^{3a} is alkyl.
59. The method or compound according to any one of Claims 1-57, wherein R^{3a} is Me, Et, or i-Pr.
60. The method or compound according to either of Claims 1 or 22, wherein the compound is according to formula Va, Vb, Vc, Vd, Ve, or Vf:




or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;

and wherein R^2 , R^5 , and R^6 are as in claim 1; each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; t is 0, 1, 2, or 3.

61. The method or compound according to either of Claims 1 or 22, wherein the compound is according to formula VIa, VIb, VIc, VId, VIe, or VIf:




or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof;

and wherein R^2 , R^5 , and R^6 are as in claim 1; each R^{5a} is alkyl, substituted alkyl, halo, haloalkyl, hydroxyalkyl, aryl, heteroaryl, CN, alkoxyalkyl, amido, hydroxyl, alkoxy or substituted alkoxy; and t is 0, 1, 2, or 3.

62. The method or compound according to any one of Claims 1-61, wherein R^2 is OH.
63. The method or compound according to any one of Claims 1-61, wherein R^2 is H, substituted or unsubstituted C_1 - C_6 alkyl, or substituted or unsubstituted phenyl.
64. The method or compound according to any one of Claims 1-61, wherein R^2 is H, Me, or Ph.
65. The method or compound according to any one of Claims 1-61, wherein R^2 is H.
66. The method or compound according to any one of Claims 21-65, wherein t is 0.
67. The method or compound according to any one of Claims 21-65, wherein t is 1 or 2; and each R^{5a} is independently OH, Ph, benzyl, or Me.
68. The method or compound according to any one of Claims 21-65, wherein t is 1; and R^{5a} is Me, Et, n-Pr, or n-Bu.
69. The method or compound according to any one of Claims 21-65, wherein t is 1; and R^{5a} is 3-Me, 3-Et, 3-n-Pr, or 3-n-Bu.
70. The method or compound according to any one of Claims 21-65, wherein t is 2; and one R^{5a} is 3-Me and the other is 5-Me.
71. The method according to any one of Claims 21-61, wherein R^5 is Me, or Et.

72. The method according to any one of Claims 21-61, wherein R^6 is Me, Et, n-Pr, n-Bu, n-pentyl, n-hexyl, or n-heptyl.
73. The method according to claim 1 or the compound according to Claim 22, wherein the compound is according to formula VIIa, VIIb, VIIc, VIId, VIIe, or VIIf:




and wherein R^{5b} is H or Me;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.


74. The method according to claim 1 or the compound according to Claim 22, wherein the compound is according to formula VIIIa, VIIIb, or VIIfc:



or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.


75. The method according to claim 1 or the compound according to Claim 22, wherein the compound is according to formula IXa, IXb, or IXc:



or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.

76. The method according to claim 1 or the compound according to Claim 22, wherein the compound is according to formula Xa, Xb, or Xc:




and wherein R^{5b} is H or Me;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.

77. The method according to claim 1 or the compound according to Claim 22, wherein the compound is according to formula XIa, XIb, or XIc:




and wherein R^{5b} is H or Me;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.

78. The method according to claim 1 or the compound according to Claim 22, wherein the compound is according to formula XIIa, XIIb, or XIIc:



and wherein R^{5b} is H or Me;

or a pharmaceutically acceptable salt, solvate or prodrug thereof;

or stereoisomers, isotopic variants and tautomers thereof.

79. A compound according to formula Xa, Xb, Xc, XIa, XIb, XIc, XIIa, XIIb, or XIIc.
80. The method according to claim 1, wherein the compound is a compound with Compound ID 99 or 101; or a pharmaceutically acceptable salt, solvate or prodrug thereof; or stereoisomers, isotopic variants and tautomers thereof.
81. The method according to claim 1, wherein the compound is Compound with Compound ID 95, 100, 111, or 139; or a pharmaceutically acceptable salt, solvate or prodrug thereof; or stereoisomers, isotopic variants and tautomers thereof.
82. A compound selected from compounds with compound IDs 99 and 101; or a pharmaceutically acceptable salt, solvate or prodrug thereof; or stereoisomers, isotopic variants and tautomers thereof.
83. A compound selected from compounds with Compound ID 95, 100, 111, and 139 or a pharmaceutically acceptable salt, solvate or prodrug thereof; or stereoisomers, isotopic variants and tautomers thereof.
84. The method according to claim 1 or the compound according to Claim 22, wherein the compound is any one of compounds listed in Table 1.
85. The method according to claim 1 or the compound according to Claim 22, wherein the compound is selected from compounds listed in Table 1; and wherein the Compound ID is 70, 79 106-108, or 142.
86. The method according to claim 1 or the compound according to Claim 22, wherein the compound is selected from compounds listed in Table 1A.
87. The method according to claim 1 or the compound according to Claim 22, wherein the compound is selected from compounds listed in Table 1B.
88. The method according to claim 1 or the compound according to Claim 22, wherein the compound is selected from compounds listed in Table 1A; and wherein the Compound ID is 202.

89. The method according to claim 1 or the compound according to Claim 22, wherein the compound is selected from compounds listed in Table 1C.
90. A compound selected from the compounds listed in Table 1.
91. Any one of compounds selected from compounds listed in Table 1; and wherein the Compound ID is 70, 79 106-108, or 142.
92. Any one of compounds selected from compounds listed in Table 1A.
93. Any one of compounds selected from compounds listed in Table 1B.
94. Any one of compounds selected from compounds listed in Table 1C.
95. The method according to claim 1 or the compound according to Claim 22, wherein the compound is a salt of Compound 99, 101, 201 or 202.
96. The method according to claim 1 or the compound according to Claim 22, wherein the compound is a sodium salt of Compound 99, 101, 201 or 202.
97. The method according to claim 1 or the compound according to Claim 22, wherein the compound is a salt of Compound 317-332, 401-405, 407-412, 414, 416, 417, or 418.
98. A pharmaceutical composition of compound according to any one of claims 1-97.
99. The method of Claim 1, wherein the disease or condition is autoimmune disease.
100. The method of Claim 1, wherein the disease or condition is inflammatory disease.
101. The method of Claim 1, wherein the disease or condition is selected from arthritis, diabetes, multiple sclerosis, uveitis, rheumatoid arthritis, psoriasis, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, atherosclerosis, H. pylori infections and ulcers resulting from such infection, and inflammatory bowel diseases.
102. The method of Claim 1, wherein the disease or condition is selected from Crohn's disease, ulcerative colitis, sprue and food allergies.
103. The method of Claim 1, wherein the disease or condition is selected from multiple sclerosis and experimental autoimmune encephalomyelitis (EAE).
104. The method of Claim 1, wherein the disease or condition is selected from rheumatoid arthritis or collagen-induced arthritis (CIA).